## THE GENERAL ASSEMBLY OF PENNSYLVANIA

## SENATE BILL No. 225 Session of 2021

INTRODUCED BY PHILLIPS-HILL, MARTIN, J. WARD, MENSCH, COLLETT, MUTH, KANE, STEFANO, AUMENT, CAPPELLETTI, BAKER, BROOKS, BOSCOLA, HUTCHINSON, SABATINA, TOMLINSON, LAUGHLIN, MASTRIANO, SANTARSIERO AND KEARNEY, MARCH 18, 2021

SENATOR DISANTO, BANKING AND INSURANCE, AS AMENDED, JUNE 23, 2021

## AN ACT

1	Amending the act of May 17, 1921 (P.L.682, No.284), entitled "An <
2	act relating to insurance; amending, revising, and
3	consolidating the law providing for the incorporation of
4	insurance companies, and the regulation, supervision, and
5	protection of home and foreign insurance companies, Lloyds
6	associations, reciprocal and inter-insurance exchanges, and
7	fire insurance rating bureaus, and the regulation and
8	supervision of insurance carried by such companies,
9	associations, and exchanges, including insurance carried by
10	the State Workmen's Insurance Fund; providing penalties; and
11	repealing existing laws," in quality healthcare-
12	accountability and protection, further providing for-
13	definitions, for responsibilities of managed care plans,
14	providing for preauthorization standards and for
15	preauthorization costs, further providing for continuity of
16	care, providing for step therapy protocols, further providing
17	for required disclosure, for operational standards and
18	providing for preauthorization and adverse determinations,
19	for appeals, for access requirements in service areas, for-
20	uniform preauthorization form, for preauthorization
21	exemptions and for data collection and reporting; and making-
22	an editorial change.
23	AMENDING THE ACT OF MAY 17, 1921 (P.L.682, NO.284), ENTITLED "AN <
24	ACT RELATING TO INSURANCE; AMENDING, REVISING, AND
25	CONSOLIDATING THE LAW PROVIDING FOR THE INCORPORATION OF
26	INSURANCE COMPANIES, AND THE REGULATION, SUPERVISION, AND
27	PROTECTION OF HOME AND FOREIGN INSURANCE COMPANIES, LLOYDS
28	ASSOCIATIONS, RECIPROCAL AND INTER-INSURANCE EXCHANGES, AND
29	FIRE INSURANCE RATING BUREAUS, AND THE REGULATION AND
30	SUPERVISION OF INSURANCE CARRIED BY SUCH COMPANIES,
31	ASSOCIATIONS, AND EXCHANGES, INCLUDING INSURANCE CARRIED BY

THE STATE WORKMEN'S INSURANCE FUND; PROVIDING PENALTIES; AND 1 REPEALING EXISTING LAWS," IN QUALITY HEALTHCARE 2 ACCOUNTABILITY AND PROTECTION, FURTHER PROVIDING FOR 3 DEFINITIONS AND FOR RESPONSIBILITIES OF MANAGED CARE PLANS, 4 PROVIDING FOR PREAUTHORIZATION REVIEW STANDARDS AND FOR 5 PREAUTHORIZATION COSTS, FURTHER PROVIDING FOR CONTINUITY OF 6 7 CARE, PROVIDING FOR STEP THERAPY, FURTHER PROVIDING FOR REQUIRED DISCLOSURE AND FOR OPERATIONAL STANDARDS AND 8 PROVIDING FOR INITIAL REVIEW OF PREAUTHORIZATION REQUESTS AND 9 ADVERSE DETERMINATIONS, FOR PREAUTHORIZATION DENIAL 10 GRIEVANCES AND FOR ACCESS REQUIREMENTS IN SERVICE AREAS; AND 11 MAKING AN EDITORIAL CHANGE. 12 13 The General Assembly of the Commonwealth of Pennsylvania 14 hereby enacts as follows: 15 Section 1. The General Assembly finds that: <---16 (1) Preauthorization of medical treatment, testing and 17 procedures was initially designed to reduce unnecessary cost 18 placed on insurers, insureds and providers. 19 (2) The process of preauthorization and the process to-20 appeal a preauthorization decision has not been updated in 20-21 vears. 22 (3) The current preauthorization process has become 23 overly expansive, to the point where it is interfering with-24 the patient provider relationship by inserting a third party-25 into the treatment decision making process. 26 (4) The basic minimum requirements of this act are-27 necessary to ensure that the patient provider relationship 28 remains paramount in making any decision on the course of-29 treatment. 30 Section 2. It is the intent of the General Assembly to 31 create clear definitions, notice requirements and processes for-32 the determination of authorizing insurance coverage for medical 33 treatment, procedures and testing prior to the patient receiving 34 the treatment, procedure and testing. 35 Section 3. The definitions of "emergency service,"-36 "enrollee," "grievance," "health care service," "prospective-

- 2 -

1	utilization review," "retrospective utilization review,"
2	"utilization review" and "utilization review entity" in section
3	2102 of the act of May 17, 1921 (P.L.682, No.284), known as The-
4	Insurance Company Law of 1921, are amended and the section is
5	amended by adding definitions to read:
6	Section 2102. Definitions. As used in this article, the
7	following words and phrases shall have the meanings given to
8	them in this section:
9	* * *
10	"Administrative defect." Any deficiency, error, mistake or
11	missing information other than medical necessity that serves as
12	the basis of an adverse determination issued by a utilization
13	review entity as justification to deny preauthorization.
14	"Adverse determination." A decision made by a utilization
15	review entity from a preauthorization request that:
16	(1) the health care services furnished or proposed to an
17	insured are not medically necessary or result from an
18	administrative denial; or
19	(2) denies, reduces or terminates benefit coverage.
20	The term includes a decision to deny a step therapy exception
21	request under section 2118. The term does not include a decision
22	to deny, reduce or terminate services that are not covered for
23	reasons other than their medical necessity or experimental or
24	investigational nature.
25	* * *
26	"Appeal." A formal request, either orally or in writing, to
27	reconsider a determination not to authorize a health care
28	service prior to the service being provided. This does not
29	include a grievance filed under section 2161, relating to
30	reconsideration of a decision made after coverage has been
202	10SB0225PN0948 - 3 -

1 provided.

2	"Appeal procedure." A formal process that permits an
3	insured, attending physician or his designee, facility or health
4	care practitioner on an insured's behalf to appeal an adverse
5	determination rendered by the utilization review entity or its
6	designee utilization review entity or agent.
7	"Authorization." A determination by a utilization review
8	entity that:
9	(1) A health care service has been reviewed and, based on
10	the information provided, satisfies the utilization review
11	entity's requirements for medical necessity.
12	(2) The health care service reviewed is a covered service.
13	(3) Payment will be made for the health care service.
14	* * *
15	"Clinical criteria." Policies, screening procedures,
16	determination rules, determination abstracts, clinical
17	protocols, practice guidelines and medical protocols that are
18	specified in a written document available for peer-to-peer_
19	review by a peer within the same profession and specialty and
20	subject to challenge by an insured, a provider or a provider
21	organization when used as a basis to withhold preauthorization,
22	deny or otherwise modify coverage and that is used by a
23	utilization review entity to determine the medical necessity of
24	health care services. The criteria shall:
25	(1) Be based on nationally recognized standards.
26	(2) Be developed in accordance with the current standards of
27	national accreditation entities.
28	(3) Reflect community standards of care.
29	(4) Ensure quality of care and access to needed health care
30	services.

20210SB0225PN0948

- 4 -

1	(5) Be evidence-based or based on generally accepted expert
2	<u>consensus standards.</u>
3	(6) Be sufficiently flexible to allow deviations from norms
4	when justified on a case by case basis.
5	(7) Be evaluated and updated if necessary at least annually.
6	"Clinical practice guidelines." A systematically developed
7	statement to assist in decision-making by health care providers
8	and enrollees relating to appropriate health care for specific
9	clinical circumstances and conditions.
10	* * *
11	"Emergency service." Any health care service provided to an
12	enrollee, including prehospital transportation or treatment by
13	emergency medical services providers, after the sudden onset of
14	a medical condition that manifests itself by acute symptoms of
15	sufficient severity or severe pain such that a prudent layperson
16	who possesses an average knowledge of health and medicine could
17	reasonably expect the absence of immediate medical attention to
18	result in:
19	(1) placing the health of the enrollee or, with respect to a
20	pregnant woman, the health of the woman or her unborn child in-
21	serious jeopardy;
22	(2) serious impairment to bodily functions; or
23	(3) serious dysfunction of any bodily organ or part.
24	Emergency transportation and related emergency service provided
25	by a licensed ambulance service shall constitute an emergency
26	service.
27	["Enrollee." Any policyholder, subscriber, covered person or-
28	other individual who is entitled to receive health care services
29	under a managed care plan.]
30	"Expedited appeal." A formal request, either orally or in

- 5 -

1	writing, to reconsider an adverse determination not to authorize
2	emergency health care services or urgent health care services.
3	"Final adverse determination." An adverse determination that
4	has been upheld by a utilization review entity at the completion
5	of the utilization review entity's internal appeals process.
6	"Grievance." As provided in subdivision (i), a request by an-
7	[enrollee] <u>insured</u> or a health care provider, with the written-
8	consent of the [enrollee] <u>insured</u> , to have a managed care plan
9	or utilization review entity reconsider a decision solely-
10	concerning the medical necessity and appropriateness of a health-
11	care service after the service has been provided to the insured.
12	If the managed care plan is unable to resolve the matter, a
13	grievance may be filed regarding the decision that:
14	(1) disapproves full or partial payment for a requested
15	health care service;
16	(2) approves the provision of a requested health care
17	service for a lesser scope or duration than requested; or
18	(3) disapproves payment for the provision of a requested
19	health care service but approves payment for the provision of an
20	alternative health care service.
21	The term [does] <u>shall</u> not include a complaint.
22	* * *
23	"Health care service." Any [covered] treatment, admission,
24	procedure, <u>test used to aid in diagnosis or the provision of the</u>
25	applicable treatment, pharmaceutical product, medical supplies
26	and equipment or other services, including behavioral health[,
27	prescribed] or otherwise provided or proposed to be provided by
28	a health care provider to an enrollee under a managed care plan-
29	<del>contract.</del>
30	* * *

- 6 -

1	"Medically necessary health care services." Health care
2	services that a prudent health care provider would provide to a
3	patient for the purpose of preventing, diagnosing or treating an
4	illness, injury, disease or its symptoms in a manner that is:
5	(1) in accordance with generally accepted standards of
6	medical practice based on clinical criteria;
7	(2) appropriate in terms of type, frequency, extent, site
8	and duration pursuant to clinical criteria; and
9	(3) not primarily for the economic benefit of the health
10	plans and purchasers or for the convenience of the patient,
11	treating physician or other health care provider.
12	"Medication assisted treatment" or "MAT." The use of
13	medications approved by the United States Food and Drug
14	Administration, including methadone, buprenorphine, alone or in
15	combination with naloxone, or naltrexone, in combination with
16	counseling and behavioral therapies, to provide a comprehensive
17	approach to the treatment of substance use disorders.
18	"NCPDP SCRIPT Standard." The National Council for
19	Prescription Drug 10 Programs SCRIPT Standard Version 201310,
20	the most recent standard adopted by the Department of Health and
21	Human Services or a subsequently related version, provided that
22	the new version is backwards compatible to the current version
23	adopted by the Department of Health and Human Services. The
24	NCPDP SCRIPT Standard applies to the provision of pharmaceutical
25	or pharmacological products.
26	"Nonurgent health care service." A health care service
27	provided to an enrollee that is not considered an emergency
28	service or an urgent health care service.
29	* * *
30	<u>"Preauthorization" or "prior authorization." The process by</u>

- 7 -

1	which a utilization review entity managed care organization or
2	health care insurer determines the medical necessity of
3	otherwise covered health care services prior to authorizing
4	coverage and the rendering of the health care services,
5	including, but not limited to, preadmission review, pretreatment
6	review, utilization and case management. The term includes a
7	health insurer's or utilization review entity's requirement that
8	an insured or health care practitioner notify the health insurer
9	or utilization review agent prior to providing a health care
10	service. This determination and any appeal therefrom shall be
11	conducted prior to the delivery or provision of a health care
12	service and result in a decision to approve or deny payment for
13	the health care service.
14	* * *
15	["Prospective utilization review." A review by a utilization-
16	review entity of all reasonably necessary supporting information
17	that occurs prior to the delivery or provision of a health care
18	service and results in a decision to approve or deny payment for-
19	the health care service.]
20	* * *
21	"Retrospective utilization [review."] review" or
22	
	<u>"retrospective review."</u> A review by a utilization review entity-
23	
23 24	<u>"retrospective review."</u> A review by a utilization review entity-
	<u>"retrospective review."</u> A review by a utilization review entity- of all reasonably necessary supporting information which occurs
24	<u>"retrospective review."</u> A review by a utilization review entity of all reasonably necessary supporting information which occurs following delivery or provision of a health care service and
24 25	<u>"retrospective review."</u> A review by a utilization review entity of all reasonably necessary supporting information which occurs following delivery or provision of a health care service and results in a decision to approve or deny payment for the health
24 25 26	<u>"retrospective review."</u> A review by a utilization review entity of all reasonably necessary supporting information which occurs following delivery or provision of a health care service and results in a decision to approve or deny payment for the health care service[.], but may not be used to review a decision to
24 25 26 27	<u>"retrospective review."</u> A review by a utilization review entity of all reasonably necessary supporting information which occurs following delivery or provision of a health care service and results in a decision to approve or deny payment for the health care service[.], but may not be used to review a decision to approve payment for health care services through

- 8 -

1	by a provider to require expedited preauthorization review in
2	the event a delay may jeopardize life or health of the insured
3	or a delay in treatment could:
4	(1) negatively affect the ability of the insured to regain
5	maximum function; or
6	(2) subject the insured to severe pain that cannot be
7	adequately managed without receiving the care or treatment that
8	is the subject of the utilization review as quickly as possible.
9	The term shall not include an emergency service or nonurgent
10	<u>health care service.</u>
11	"Utilization review." A system of prospective, concurrent or-
12	retrospective utilization review performed by a utilization
13	review entity of the medical necessity and appropriateness of
14	health care services prescribed, provided or proposed to be-
15	provided to an enrollee. The term includes preauthorization, but
16	does not include any of the following:
17	(1) Requests for clarification of coverage, eligibility or
18	health care service verification.
19	(2) A health care provider's internal quality assurance or
20	utilization review process unless the review results in denial
21	of payment for a health care service.
22	"Utilization review entity." Any entity certified pursuant
23	to subdivision (h) that performs utilization review on behalf of
24	a managed care plan. <u>The term includes:</u>
25	(1) an employer with employes in this Commonwealth who are
26	covered under a health benefit plan or health insurance policy;
27	(2) an insurer that writes health insurance policies,
28	including preferred provider organizations defined in section
29	<del>630;</del>
30	(3) pharmacy benefits managers responsible for managing

- 9 -

1	access of insureds to available pharmaceutical or
2	pharmacological care;
3	(4) any other individual or entity that provides, offers to
4	provide or administers hospital, outpatient, medical or other
5	health benefits to an individual treated by a health care
6	provider in this Commonwealth under a policy, plan or contract;
7	
8	(5) a health insurer if the health insurer performs
9	utilization review.
10	Section 4. Section 2111 of the act is amended by adding
11	paragraphs to read:
12	Section 2111. Responsibilities of Managed Care Plans A-
13	managed care plan shall do all of the following:
14	* * *
15	(14) Make updates to its enrollment eligibility information
16	within thirty (30) days of receiving updated enrollment
17	information. Updates in enrollment eligibility may occur due to
18	new enrollments, coordination of benefits or termination of
19	benefits. If a managed care plan fails to update eligibility
20	information in a timely manner, the managed care plan may not
21	deny payment due to enrollment information being inaccurate for
22	a date of service if current eligibility information was
23	available. In the event of a retroactive termination or a
24	determination that an enrollee was ineligible for benefits, a
25	health plan may recover any payments made in error within thirty
26	(30) days of the date of service.
27	(15) When establishing rules pertaining to the timely filing
28	of health care provider claims, provide that a health care
29	provider's filing requirement will commence based on the
30	following, whichever occurs latest:

- 10 -

1	(	$+ h \circ$	+ imo	of	nationt	diachargo.	010
$\perp$	$T \pm J$	CITE	CINC	01	patrent	urscharge,	-OF
					-	-	

±	(1) the time of patient disenarge, of
2	(ii) when authorization or approval is confirmed by the
3	<u>managed care plan.</u>
4	Section 5. The act is amended by adding sections to read:
5	Section 2114. Preauthorization Standards. (a) No later
6	than one hundred eighty (180) days after the effective date of
7	this section, preauthorization requests shall be accessible to
8	health care providers and accepted by insurers, managed care
9	organizations and utilization review organizations
10	electronically through a secure electronic transmission
11	platform. The electronic preauthorization requirements under
12	this subsection shall not apply:
13	(1) under circumstances when electronic transmission is not
14	available to be issued or received due to a temporary
15	technological or electrical failure and, in the instance of a
16	temporary technological failure, a practitioner shall, within
17	seventy two (72) hours, seek to correct any cause for the
18	failure that is reasonably within the practitioner's control.
19	(2) when a practitioner who or health care facility that
20	does not have either of the following:
21	(i) Internet access; or
22	<u>(ii) an electronic health record system.</u>
23	(b) NCPDP SCRIPT Standard shall be acceptable for
24	pharmaceutical or pharmacological care, subject to the terms and
25	<u>limitations under subsection (a).</u>
26	(c) Any restriction that a utilization review entity places
27	on the preauthorization of health care services shall be:
28	(1) based on the medical necessity of those services and on
29	<u>clinical criteria;</u>
30	(2) applied consistently; and

1	(3) disclosed by the managed care plan or utilization review
2	entity pursuant to section 2136.
3	(d) Adverse determinations and final adverse determinations
4	made by a utilization review entity or agent thereof shall be
5	<u>based on clinical criteria.</u>
6	(e) A utilization review entity shall not deny coverage of a
7	health care service solely based on the grounds that the health
8	care service does not meet clinical criteria.
9	(f) Preauthorization shall not be required:
10	(1) where a medication, including noncontrolled generic
11	medication or procedure prescribed for a patient is customary
12	and properly indicated or is a treatment for the clinical
13	indication as supported by peer reviewed medical publications;
14	<u>or</u>
15	(2) for the provision of MAT for the treatment of an opioid
16	<u>use disorder.</u>
16 17	<u>(f.1) A managed care plan may not deny preauthorization for</u>
-	
17	(f.1) A managed care plan may not deny preauthorization for
17 18	(f.1) A managed care plan may not deny preauthorization for a health care service for an insured currently managed with an
17 18 19	(f.1) A managed care plan may not deny preauthorization for a health care service for an insured currently managed with an established treatment regimen or for continuity of care. The
17 18 19 20	(f.1) A managed care plan may not deny preauthorization for a health care service for an insured currently managed with an established treatment regimen or for continuity of care. The continued care may not be subject to concurrent review if the
17 18 19 20 21	(f.1) A managed care plan may not deny preauthorization for a health care service for an insured currently managed with an established treatment regimen or for continuity of care. The continued care may not be subject to concurrent review if the treatment regimen or continuity of care follows from a previous
17 18 19 20 21 22	(f.1) A managed care plan may not deny preauthorization for a health care service for an insured currently managed with an established treatment regimen or for continuity of care. The continued care may not be subject to concurrent review if the treatment regimen or continuity of care follows from a previous preauthorization approval.
17 18 19 20 21 22 23	<u>(f.1) A managed care plan may not deny preauthorization for</u> <u>a health care service for an insured currently managed with an</u> <u>established treatment regimen or for continuity of care. The</u> <u>continued care may not be subject to concurrent review if the</u> <u>treatment regimen or continuity of care follows from a previous</u> <u>preauthorization approval.</u> <u>(g) If a provider contacts a utilization review entity</u>
17 18 19 20 21 22 23 24	(f.1) A managed care plan may not deny preauthorization for a health care service for an insured currently managed with an established treatment regimen or for continuity of care. The continued care may not be subject to concurrent review if the treatment regimen or continuity of care follows from a previous preauthorization approval. (g) If a provider contacts a utilization review entity seeking preauthorization, a medically necessary health care
17 18 19 20 21 22 23 24 25	(f.1) A managed care plan may not deny preauthorization for a health care service for an insured currently managed with an established treatment regimen or for continuity of care. The continued care may not be subject to concurrent review if the treatment regimen or continuity of care follows from a previous preauthorization approval. (g) If a provider contacts a utilization review entity seeking preauthorization, a medically necessary health care service and the utilization review entity, through any agent,
17 18 19 20 21 22 23 24 25 26	<pre>(f.1) A managed care plan may not deny preauthorization for a health care service for an insured currently managed with an established treatment regimen or for continuity of care. The continued care may not be subject to concurrent review if the treatment regimen or continuity of care follows from a previous preauthorization approval. (g) If a provider contacts a utilization review entity seeking preauthorization, a medically necessary health care service and the utilization review entity, through any agent, contractor, employe or representative informs the provider that</pre>
17 18 19 20 21 22 23 24 25 26 27	<pre>(f.1) A managed care plan may not deny preauthorization for a health care service for an insured currently managed with an established treatment regimen or for continuity of care. The continued care may not be subject to concurrent review if the treatment regimen or continuity of care follows from a previous preauthorization approval. (g) If a provider contacts a utilization review entity seeking preauthorization, a medically necessary health care service and the utilization review entity, through any agent, contractor, employe or representative informs the provider that preauthorization is not required for the particular service that</pre>
17 18 19 20 21 22 23 24 25 26 27 28	<pre>(f.1) A managed care plan may not deny preauthorization for a health care service for an insured currently managed with an established treatment regimen or for continuity of care. The continued care may not be subject to concurrent review if the treatment regimen or continuity of care follows from a previous preauthorization approval. (g) If a provider contacts a utilization review entity seeking preauthorization, a medically necessary health care service and the utilization review entity, through any agent, contractor, employe or representative informs the provider that preauthorization is not required for the particular service that is sought, coverage for the service shall be deemed approved.</pre>

1	respond to preauthorization requests under the pharmacy benefit
2	through a secure electronic transmission using the NCPDP SCRIPT
3	Standard ePA transactions.
4	Section 2115. Preauthorization Costs. (a) In the event
5	that an insured is covered by more than one health plan that
6	requires preauthorization:
7	(1) If preauthorization for a health care service has
8	been approved by a primary insurer, then a secondary insurer
9	or defined benefits plan may not refuse payment for health
10	care services solely on the basis that the procedures of the
11	secondary insurer for preauthorization were not followed.
12	(2) Nothing in this section shall be construed to
13	preclude a secondary insurer or defined benefits plan from
14	preauthorizing a health care service that may have been
15	denied preauthorization by a primary insurer.
16	(b) An appeal of an adverse determination or external review
17	of a final adverse determination shall be provided without
18	charge to the insured or insured's health care provider.
19	Section 6. Section 2117 of the act is amended by adding
20	subsections to read:
21	Section 2117. Continuity of Care* * *
22	(g) If the appeal of an adverse determination of a
23	preauthorization request concerns ongoing health care services
24	that are being provided pursuant to an initially authorized
25	admission or course of treatment, the health care services shall
26	be continued to be paid and provided without liability to the
27	insured or insured's health care provider until the latest of:
28	(1) thirty (30) days following the insured or insured's
29	health care provider's receipt of a notice of final adverse
30	determination satisfying the requirements of this act, if the

1	decision on adverse determination has been appealed through an
2	external review proceeding;
3	(2) the duration of treatment; or
4	<u>(3) sixty (60) days.</u>
5	(h) The insured shall receive services for the longest
6	possible time calculated under this section.
7	(i) The insurer shall not be permitted to retroactively
8	review the decision to approve and provide health care services
9	through preauthorization, including preauthorizing for extending
10	the term or course of treatment.
11	(j) Notwithstanding any other provision of law, the insurer
12	shall not retroactively recover the cost of treatment either for
13	the initial period of treatment or the period of treatment
14	provided to the insured as part of the decision making process
15	to authorize coverage of additional treatment periods.
16	Section 7. The act is amended by adding a section to read:
17	Section 2118. Step Therapy. (a) The following shall apply:
18	(1) Clinical review criteria used to establish a step
19	therapy protocol shall be based on clinical practice guidelines
20	that:
21	(i) Recommend that the prescription drugs be taken in the
22	specific sequence required by the step therapy protocol.
23	(ii) Are developed and endorsed by a multidisciplinary panel
24	of experts that manages conflicts of interest among the members
25	of the writing and review groups by:
26	(A) Requiring members to disclose any potential conflict of
27	interests with entities, including insurers, health plans and
28	pharmaceutical manufacturers and recuse themselves from voting
29	<u>if the member has a conflict of interest.</u>
30	(B) Using a methodologist to work with writing groups to

1	<u>provide objectivity in data analysis and ranking of evidence</u>
2	through the preparation of evidence tables and facilitating
3	<u>consensus.</u>
4	(C) Offering opportunities for public review and comments.
5	(iii) Are based on high quality studies, research and
6	<u>medical practice.</u>
7	(iv) Are created by an explicit and transparent process
8	that:
9	(A) minimizes biases and conflicts of interest;
10	(B) explains the relationship between treatment options and
11	outcomes;
12	(C) rates the quality of the evidence supporting
13	recommendations; and
14	(D) considers relevant patient subgroups and preferences.
15	(v) Are continually updated through a review of new_
16	evidence, research and newly developed treatments.
17	(2) In the absence of clinical guidelines that meet the
18	requirements under paragraph (1), peer reviewed publications may
19	be substituted.
20	(3) When establishing a step therapy protocol, a utilization
21	review agent shall also take into account the needs of atypical
22	patient populations and diagnoses when establishing clinical
23	<del>review criteria.</del>
24	(4) An insurer, pharmacy benefit manager or utilization
25	review organization shall:
26	(i) upon written request, provide all specific written
27	<u>clinical review criteria relating to the particular condition or</u>
28	<u>disease, including clinical review criteria relating to a step</u>
29	therapy protocol override determination; and
30	(ii) make the clinical review criteria and other clinical

- 15 -

1	information available on its publicly accessible Internet
2	website and to a health care professional on behalf of an
3	<u>insured upon written request.</u>
4	(5) This subsection shall not be construed to require
5	insurers, health plans or the Commonwealth to set up a new_
6	<u>entity to develop clinical review criteria used for step therapy</u>
7	protocols.
8	(b) The following shall apply:
9	(1) When coverage of a prescription drug for the treatment
10	of any medical condition is restricted for use by an insurer,
11	health plan or utilization review organization through the use
12	of a step therapy protocol, the patient and prescribing
13	practitioner shall have access to a clear, readily accessible
14	and convenient process to request a step therapy exception. An
15	<u>insurer, health plan or utilization review organization may use</u>
16	its existing medical exceptions process to satisfy this
17	requirement. The process shall be made easily accessible on the
18	<u>publicly accessible Internet website of the insurer, health plan</u>
19	<u>or utilization review organization. An insurer, health plan or</u>
20	utilization review organization must disclose all rules and
21	<u>criteria related to the step therapy protocol upon request to</u>
22	all prescribing practitioners, including the specific
23	information and documentation that must be submitted by a
24	prescribing practitioner or patient to be considered a complete
25	exception request.
26	(2) A step therapy exception shall be granted if:
27	(i) The required prescription drug is contraindicated or
28	will likely cause an adverse reaction by or physical or mental
29	harm to the patient.
30	(ii) The required prescription drug is expected to be

- 16 -

1	ineffective based on the known clinical characteristics of the
2	patient and the known characteristics of the prescription drug
3	regimen.
4	(iii) The patient has tried the required prescription drug
5	while under the patient's current or previous health insurance
6	or health benefit plan, or another prescription drug in the same
7	pharmacologic class or with the same mechanism of action, and
8	the prescription drug was discontinued due to lack of efficacy
9	or effectiveness, diminished effect or an adverse event.
10	(iv) The required prescription drug is not in the best
11	interest of the patient, based on medical necessity.
12	(v) The patient is stable on a prescription drug selected by
13	the patient's health care provider for the medical condition
14	under consideration while on a current or previous health
15	<u>insurance or health benefit plan.</u>
16	(3) Upon the granting of a step therapy exception, the
17	insurer, health plan or utilization review organization shall
18	authorize coverage for the prescription drug prescribed by the
19	patient's treating health care provider.
20	(4) The insurer, health plan or utilization review
21	organization shall grant or deny a step therapy exception
22	request or an appeal within seventy-two (72) hours of receipt.
23	The following shall apply:
24	(i) In cases where exigent circumstances exist, an insurer,
25	health plan or utilization review organization shall respond
26	<u>within twenty four (24) hours of receipt.</u>
27	(ii) If a request for a step therapy override exception is
28	incomplete or additional clinically relevant information is
29	required, the insurer, health plan or utilization review
30	organization shall notify the prescribing practitioner within

1	seventy two (72) hours of submission, or twenty four (24) hours
2	in exigent circumstances, what additional or clinically relevant
3	information is required in order to approve or deny the step
4	therapy exception request or appeal under this section.
5	(iii) Once the requested information is submitted, the
6	applicable time period to grant or deny a step therapy exception
7	request or appeal shall apply.
8	(iv) Should a determination or request for incomplete or
9	clinically relevant information by an insurer, health plan or
10	utilization review organization not be received by the
11	prescribing practitioner within the time allotted, the exception
12	<u>or appeal shall be deemed granted.</u>
13	(v) In the event of a denial, the insurer, health plan or
14	utilization review organization must inform the patient of a
15	potential appeal process.
16	(5) Any step therapy exception under this subsection shall
17	be eligible for appeal by an insured.
18	(6) This subsection shall not be construed to prevent:
19	(i) An insurer, health plan or utilization review
20	<u>organization from requiring a patient to try an AB rated generic</u>
21	equivalent or interchangeable biological product, as defined in
22	<u>42 U.S.C. § 262(i)(3) (relating to regulation of biological</u>
23	products), unless the requirement meets any of the criteria
24	under this subsection for a step therapy exception request,
25	prior to providing coverage for the equivalent branded
26	prescription drug;
27	(ii) An insurer, health plan or utilization review
28	organization from requiring a pharmacist to effect substitutions
29	of prescription drugs consistent with the laws of this
30	<u>Commonwealth.</u>

1	(iii) A health care provider from prescribing a prescription
2	drug that is determined to be medically appropriate.
3	(c) Notwithstanding any provision of law to the contrary,
4	the Insurance Department shall promulgate any regulations
5	necessary to enforce this section.
6	(d) An insurer, health plan or a utilization review
7	organization shall annually report to the Insurance Department,
8	in a format prescribed by the Insurance Department:
9	(i) the number of step therapy exception requests received
10	by exception;
11	(ii) the type of health care providers or the medical
12	specialties of the health care providers submitting step therapy
13	exception requests;
14	(iii) the number of step therapy exception requests by
15	exception that were denied and the reasons for the denials;
16	(iv) the number of step therapy exception requests by
17	exception that were approved;
18	(v) the number of step therapy exception requests by
19	exception that were initially denied and then appealed;
20	(vi) the number of step therapy exception requests by
21	exception that were initially denied and then subsequently
22	reversed by internal appeals or external reviews; and
23	(vii) the medical conditions for which patients are granted
24	exceptions due to the likelihood that switching from the
25	<u>prescription drug will likely cause an adverse reaction by or</u>
26	physical or mental harm to the insured.
27	(e) As used in this section, the following words and phrases
28	shall have the meanings given to them in this subsection unless
29	the context clearly indicates otherwise:
30	"Clinical practice guidelines." A systematically developed

- 19 -

1	statement to assist decision making by health care providers and
2	patient decisions about appropriate healthcare for specific
3	clinical circumstances and conditions.
4	"Clinical review criteria." The written screening
5	procedures, decision abstracts, clinical protocols and practice
6	guidelines used by an insurer, health plan or utilization review
7	organization to determine the medical necessity and
8	appropriateness of healthcare services.
9	"Medically necessary." Health services and supplies that
10	under the applicable standard of care are appropriate:
11	(1) to improve or preserve health, life or function;
12	(2) to slow the deterioration of health, life or
13	function; or
14	(3) for the early screening, prevention, evaluation,
15	diagnosis or treatment of a disease, condition, illness or
16	<u>injury.</u>
17	"Step therapy exception." When a step therapy protocol
18	should be overridden in favor of immediate coverage of the
19	health care provider's selected prescription drug.
20	"Step therapy protocol." A protocol, policy or program that
21	establishes the specific sequence in which prescription drugs
22	for a specified medical condition and medically appropriate for
23	a particular patient are covered by an insurer or health plan.
24	"Utilization review organization." An entity that conducts
25	utilization review, other than an insurer or health plan
26	performing utilization review for its own health benefit plans.
27	Section 8. Article XXI, Subdivision (f) subheading of the
28	act is amended to read:
29	(f) Information for Enrollees and Health Care Providers.
30	Section 9. Section 2136 of the act is amended by adding a
202	- 20 -

1	subsection to read:
2	Section 2136. Required Disclosure. * * *
3	(c) If a utilization review entity intends to implement a
4	new preauthorization requirement or restriction or amend an
5	existing requirement or restriction, the utilization review
6	entity shall provide contracted health care providers and
7	insureds with written notice of the new or amended requirement
8	or amendment not less than sixty (60) days before the
9	requirement or restriction is implemented. The notice shall be
10	in writing which may be satisfied by any of the following:
11	(1) certified mail return receipt requested;
12	(2) electronic mail read receipt requested;
13	(3) publication on the publicly accessible Internet
14	website of the insurer with an electronic mail message to
15	providers and insureds that identifies the location of the
16	publication on the website;
17	(4) web-exchange, provided that an electronic mail
18	message on how to access the web exchange is sent to the
19	providers and insured; or
20	(5) any other contractually agreed upon method,
21	specifying the details of the communication which include
22	some proof of receipt by the providers and insureds.
23	Section 10. Section 2152(a)(4) and (6) of the act are
24	amended and the section is amended by adding subsections to
25	read:
26	Section 2152. Operational Standards(a) A utilization-
27	review entity shall do all of the following:
28	* * *
29	(4) Conduct utilization reviews based on the medical
30	necessity and appropriateness of the health care service being
202	- 21 -

1	reviewed and provide notification within the following time-
2	frames:
3	(i) A prospective utilization review decision shall be
4	communicated within two (2) business days of the receipt of all
5	supporting information reasonably necessary to complete the
6	<del>review.</del>
7	(ii) A concurrent utilization review decision shall be-
8	communicated within one (1) business day of the receipt of all
9	supporting information reasonably necessary to complete the
10	<del>review.</del>
11	(iii) A retrospective utilization review decision shall be
12	communicated within thirty (30) days of the receipt of all
13	supporting information reasonably necessary to complete the
14	<del>review.</del>
15	(iv) A utilization review entity shall allow an insured and
16	the insured's health care provider a minimum of one (1) business
17	day following an inpatient admission pursuant to an emergency
18	<u>health care service or urgent health care service to notify the</u>
19	utilization review entity of the admission and any health care
20	services performed.
21	* * *
22	(6) Provide all decisions in writing to include the basis
23	and clinical rationale for the decision. For adverse
24	determinations of preauthorization decisions, a utilization
25	review entity shall provide all decisions to the insured and the
26	insured's health care provider, which decisions shall also
27	include instructions concerning how an appeal may be perfected.
28	Utilization review entities may not retroactively review the
29	medical necessity of a preauthorization that has been previously
30	approved or granted.

1	* * *
2	(9) Post to the utilization review entity's publicly
3	accessible Internet website:
4	(i) A current list of services and supplies requiring
5	preauthorization.
6	(ii) Written clinical criteria for preauthorization
7	decisions.
8	(10) Ensure that a preauthorization shall be valid for no
9	less than one hundred eighty (180) days or the duration of
10	treatment, whichever is greater, from the date the health care
11	provider receives the preauthorization so long as the insured is
12	a member of the plan. A duration of less than one hundred and
13	<u>eighty (180) days may be approved upon an agreement between a</u>
14	provider and payer.
15	(11) When performing preauthorization, only request copies
16	of medical records if a difficulty develops in determining the
17	medical necessity of a health care service. In that case, the
18	utilization review agent may only request the necessary and
19	relevant sections of the medical record.
20	(12) Not deny preauthorization nor delay preauthorization
21	for administrative defects. In the event an administrative
22	defect is discovered, a managed care plan shall allow a health
23	care provider the opportunity to remedy the administrative
24	defect within thirty (30) days of receiving notice.
25	* * *
26	(e) Failure by a utilization review entity to comply with
27	deadlines and other requirements specified for preauthorization
28	shall result in the health care service subject to review to be
29	deemed preauthorized and paid by the managed care plan.
30	(f) A utilization review entity shall approve claims for
202	10SB0225PN0948 - 23 -

- 23 -

1	health care services for which a preauthorization was required
2	and received from the managed care plan prior to the rendering
3	of the health care services, unless one of the following occurs:
4	(1) The enrollee was not eligible for coverage at the time
5	the health care service was rendered. A managed care plan may
6	not deny payment for a claim on this basis if the enrollee's
7	coverage was retroactively terminated more than one hundred
8	twenty (120) days after the date of service, provided the claim
9	is submitted timely. If the claim is submitted after the timely
10	filing deadline, the managed care plan shall have no more than
11	thirty (30) days after the claim is received to deny the claim
12	on the basis the enrollee was not eligible for coverage on the
13	date of the health care service.
14	(2) The preauthorization was based on materially inaccurate
15	or incomplete information provided by the enrollee, the
16	enrollee's designee or the health care provider, such that if
17	the correct or complete information had been provided, the
18	preauthorization would not have been granted.
19	(3) There is a reasonable basis supported by material facts
20	available for review that the enrollee, the enrollee's designee
21	or the health care provider has engaged in fraud or abuse.
22	Section 11. The act is amended by adding sections to read:
23	Section 2161.1. Preauthorization and Adverse
24	<u>Determinations. (a) A utilization review entity shall ensure</u>
25	that:
26	(1) Preauthorization is made by a qualified licensed health
27	care provider who has knowledge of the items, services,
28	products, tests or procedures submitted for preauthorization.
29	(2) Adverse determinations are made by a physician. The
30	reviewing physician must possess a current and valid

- 24 -

1	nonrestricted license to practice medicine in this Commonwealth
2	and be board certified. The insurer shall make available a
3	physician in a like specialty if the review requires a peer-to-
4	peer review in the specialty or subspecialty or a review is
5	requested by the submitting provider. A utilization review_
6	entity may seek approval from the Insurance Commissioner to use
7	a reviewing physician that is not board certified due to
8	unavailability or difficulty in finding a board certified
9	reviewing physician in a given specialty. The Insurance
10	Commissioner shall develop a form and parameters for the
11	requests and shall transmit all requests as notices to the
12	Legislative Reference Bureau for publication in the Pennsylvania
13	Bulletin. The Insurance Commissioner shall provide at least ten
14	(10) days for comment before rendering a decision, which
15	decision shall be transmitted to the Legislative Reference
16	Bureau as a separate notice for publication in the Pennsylvania
16 17	<u>Bureau as a separate notice for publication in the Pennsylvania</u> <u>Bulletin.</u>
-	
17	Bulletin.
17 18	Bulletin.
17 18 19	Bulletin. (b) Notification of a preauthorization shall be accompanied by a unique preauthorization number and indicate:
17 18 19 20	Bulletin. (b) Notification of a preauthorization shall be accompanied by a unique preauthorization number and indicate: (1) The specific health care services preauthorized.
17 18 19 20 21	Bulletin. (b) Notification of a preauthorization shall be accompanied by a unique preauthorization number and indicate: (1) The specific health care services preauthorized. (2) The next date for review.
17 18 19 20 21 22	Bulletin. (b) Notification of a preauthorization shall be accompanied by a unique preauthorization number and indicate: (1) The specific health care services preauthorized. (2) The next date for review. (3) The total number of days approved.
17 18 19 20 21 22 23	Bulletin.         (b) Notification of a preauthorization shall be accompanied         by a unique preauthorization number and indicate:         (1) The specific health care services preauthorized.         (2) The next date for review.         (3) The total number of days approved.         (4) The date of admission or initiation of services, if
17 18 19 20 21 22 23 24	Bulletin. (b) Notification of a preauthorization shall be accompanied by a unique preauthorization number and indicate: (1) The specific health care services preauthorized. (2) The next date for review. (3) The total number of days approved. (4) The date of admission or initiation of services, if applicable.
17 18 19 20 21 22 23 24 25	Bulletin.         (b) Notification of a preauthorization shall be accompanied         by a unique preauthorization number and indicate:         (1) The specific health care services preauthorized.         (2) The next date for review.         (3) The total number of days approved.         (4) The date of admission or initiation of services, if         applicable.         (c) Neither the utilization review entity nor the payer or
17 18 19 20 21 22 23 24 25 26	Bulletin.         (b) Notification of a preauthorization shall be accompanied         by a unique preauthorization number and indicate:         (1) The specific health care services preauthorized.         (2) The next date for review.         (3) The total number of days approved.         (4) The date of admission or initiation of services, if         applicable.         (c) Neither the utilization review entity nor the payer or         health insurer that has retained the utilization review entity
17 18 19 20 21 22 23 24 25 26 27	Bulletin.         (b) Notification of a preauthorization shall be accompanied         by a unique preauthorization number and indicate:         (1) The specific health care services preauthorized.         (2) The next date for review.         (3) The total number of days approved.         (4) The date of admission or initiation of services, if         applicable.         (c) Neither the utilization review entity nor the payer or health insurer that has retained the utilization review entity

1	preauthorization for one (1) service but the service provided is
2	not an exact match to the service that was preauthorized, but
3	the service does not materially depart from the service that was
4	preauthorized, a health plan shall not deny payment for the
5	service only if:
6	(1) the date of service differs by less than thirty (30)
7	<u>days;</u>
8	(2) the physician or health care provider rendering the
9	service differs from the physician or health care provider that
10	was indicated on the preauthorization, but is otherwise licensed
11	and qualified to provide the preauthorized service; or
12	(3) the service provided is different than what was
13	preauthorized but is commonly and appropriately a substitute
14	<u>based on common procedural terminology.</u>
15	(e) If the denial of preauthorization is conditioned upon
16	incomplete information or administrative error, the health plan
17	shall allow the health care provider to resubmit the claim with
18	corrected information for appropriate reimbursement up to thirty
19	(30) days after receiving notice.
20	(f) (1) If a utilization review entity questions the
21	medical necessity of a health care service, the utilization
22	review entity shall notify the insured's health care provider
23	that medical necessity is being questioned and provide the basis
24	of the challenge in sufficient detail to allow the provider to
25	meaningfully address the concern of the utilization review
26	entity prior to issuing an adverse determination.
27	(2) The insured's health care provider or the health care
28	provider's designee and the insured or insured's designee shall
29	have the right to discuss the medical necessity of the health
30	care service with the utilization review physician.

- 26 -

1	(3) A utilization review entity questioning medical
2	necessity of a health care service which may result in an
3	adverse determination shall make the reviewing physician or a
4	physician who is part of a team making the decision available
5	telephonically between the hours of seven (7) o'clock
6	<u>antemeridian and seven (7) o'clock postmeridian.</u>
7	(g) When making a determination based on medical necessity,
8	<u>a utilization review entity shall base the determination on an</u>
9	insured's presenting symptoms, diagnosis and information
10	available through the course of treatment or at the time of
11	admission or presentation at the emergency department.
12	(h) In the event a utilization review entity determines an
13	alternative level of care is appropriate, the utilization review
14	entity shall provide and cite the specific criteria used as the
15	basis for the level of care determination to the health care
16	provider, prior to denial to enable a meaningful peer to peer
17	review. If, after the peer-to-peer has been completed, denial
18	remains the determination, the health care provider shall have
19	the right to appeal the determination.
20	(i) A utilization review entity may not issue an adverse
21	determination for a procedure due to lack of preauthorization if
22	the procedure is medically necessary or clinically appropriate
23	for the patient's medical condition and rendered at the same
24	time as a related procedure for which preauthorization was
25	required and received.
26	(j) A utilization review entity shall make a
27	preauthorization or adverse determination and notify the insured
28	and the insured's health care practitioner as follows:
29	(1) For nonurgent health care services, within seventy-two-
30	(72) hours of obtaining all the necessary information to make

- 27 -

1	the preauthorization or adverse determination.
2	(2) For urgent health care services, within twenty-four (24)
3	hours of obtaining all the necessary information to make the
4	preauthorization or adverse determination.
5	(k) No utilization review entity may require
6	preauthorization for an emergency service, including
7	postevaluation and poststabilization services.
8	<u>Section 2161.2. Appeals. (a) An insured or the insured's</u>
9	health care provider may request an expedited appeal of an
10	adverse determination via telephone, facsimile, electronic mail
11	or other expeditious method. Within one (1) day of receiving an
12	expedited appeal and all information necessary to decide the
13	appeal, the utilization review entity shall provide the insured
14	and the insured's health care provider written confirmation of
15	the expedited review determination.
16	(b) An appeal shall be reviewed only by a physician who
17	satisfies any of the following conditions:
18	(1) Is board certified in the same specialty as a health
19	care practitioner who typically manages the medical condition or
20	<u>disease.</u>
21	(2) Is currently in active practice, provided that in events
22	where circumstances justify it or where the provider seeking
23	preauthorization specifically requests a health care provider
24	actively engaged in the specialty who typically manages the
25	medical condition or disease, the physician shall be made
26	available for the review.
27	(3) Is knowledgeable of, and has experience in, providing
28	the health care services under appeal.
29	(4) Is under contract with a utilization review entity to
30	perform reviews of appeals and payment of fees due under the

- 28 -

1	contract, but the performance and payment is not subject to or
2	contingent upon the outcome of the appeal.
3	The physician may also be subject to a provider agreement
4	with the insurer as a provider, but may not receive any other
5	fee or compensation from the insurer. The physician's receipt of
6	compensation from the utilization review entity shall not be
7	considered by the physician in determining the conclusion
8	reached by the physician. The physician shall at all times
9	render independent and accurate medical judgment in reaching an
10	opinion or conclusion. Failure to comply with this provision
11	shall render the physician subject to licensure disciplinary
12	action by the appropriate State licensing board.
13	(5) Not involved in making the adverse determination.
14	(6) Familiar with all known clinical aspects of the health
15	care services under review, including, but not limited to, all
16	pertinent medical records provided to the utilization review
17	entity by the insured's health care provider and any relevant
18	record provided to the utilization review entity by a health
19	care facility.
20	(c) The utilization review entity shall ensure that appeal
21	procedures satisfy the following requirements:
22	(1) The insured and the insured's health care provider may
23	challenge the adverse determination and have the right to appear
24	in person before the physician who reviews the adverse
25	determination.
26	(2) The utilization review entity shall provide the insured
27	and the insured's health care provider with written notice of
28	the time and place concerning where the review meeting will take
29	place. Notice shall be given to the insured's health care
30	provider at least fifteen (15) days in advance of the review

- 29 -

1 <u>meeting.</u>

0	
2	(3) If the insured or the insured's health care provider
3	appear in person, the utilization review entity shall offer the
4	<u>insured or insured's health care provider the opportunity to</u>
5	communicate with the reviewing physician, at the utilization
6	review entity's expense, by conference call, video conferencing
7	<u>or other available technology.</u>
8	(4) The physician performing the review of the appeal shall
9	consider all information, documentation or other material
10	submitted in connection with the appeal without regard to
11	whether the information was considered in making the adverse
12	determination.
13	(d) The following deadlines shall apply to the utilization
14	review entities:
15	(1) A utilization review entity shall decide an expedited
16	appeal and notify the insured and the insured's health care
17	provider of the determination within three (3) days after
18	receiving a notice of expedited appeal by the insured or the
19	insured's health care provider and all information necessary to
20	decide the appeal.
21	(2) A utilization review entity shall issue a written
22	determination concerning a nonexpedited appeal not later than
23	<u>thirty (30) days after receiving a notice of appeal from an</u>
24	insured or insured's health care provider and all information
25	necessary to decide the appeal.
26	(e) Written notice of final adverse determinations shall be
27	provided to the insured and the insured's health care provider.
28	(f) If the insured or the insured's health care provider or
29	a designee on behalf of either the insured or the insured's
30	health care provider has satisfied all necessary requirements

1	for the appeal of an adverse determination through the
2	preauthorization process and the appeal has resulted in a
3	continued adverse determination either based on lack of medical
4	necessity or an administrative defect, the insured, the
5	insured's health care provider or a designee on behalf of either
6	the insured or the insured's health care provider or a designee
7	may file a consumer complaint with the Insurance Department. The
8	complaint shall be adjudicated without unnecessary delay and a
9	determination issued by the Insurance Department with
10	appropriate sanctions, if applicable, pursuant to the authority
11	given to the Insurance Department.
12	(g) To the extent that an insured, an insured's health care
13	provider or a designee on behalf of either the insured or the
14	insured's health care provider or a designee files a consumer
15	complaint with the department or the Office of Attorney General
16	pursuant to their authority to receive such complaints, a copy
17	of the complaint filed with either the department or the Office
18	of Attorney General shall be forwarded to the Insurance
19	Department and the copy shall serve as a new consumer complaint
20	to be adjudicated pursuant to the terms of this section and all
21	other applicable law.
22	(h) Nothing in this section shall be construed to preclude
23	an insured or an insured's designee the ability to file a
24	separate consumer complaint with the Insurance Department for
25	failure to comply with the requirements of this act as it
26	applies to preauthorization processes or denial of health
27	insurance coverage generally.
28	<u>Section 2195. Access Requirements in Service Areas. If a</u>
29	patient's safe discharge is delayed for any reason, including
30	lack of available posthospitalization services, including, but

- 31 -

1	not limited to, skilled nursing facilities, home health services
2	and postacute rehabilitation, the managed care plan shall
3	reimburse the hospital for each subsequent date of service at
4	the greater of the contracted rate with the managed care plan
5	for the current level of care and service or the full diagnostic
6	related group payment divided by the mean length of stay for the
7	<u>particular diagnostic related group.</u>
8	Section 2196. Uniform Preauthorization Form(a) Within-
9	three (3) months of the effective date of this section, the
10	Insurance Department shall convene a panel to develop a uniform
11	preauthorization form that all health care providers in this
12	<u>Commonwealth shall use to request preauthorization and that all</u>
13	<u>health insurers shall accept as sufficient to request</u>
14	preauthorization of health care services.
15	(b) The panel shall consist of not fewer than ten (10)
16	persons. Equal representation shall be afforded to the
17	physician, health care facility, employer, health insurer and
18	consumer protection communities within this Commonwealth.
19	(c) Within one (1) year of the effective date of this
20	section, the panel shall conclude development of the uniform
21	preauthorization form and the Insurance Department shall make
22	the uniform preauthorization form available to health care
23	providers in this Commonwealth and utilization review entities
24	and agents.
25	Section 2197. Preauthorization Exemptions. A health care
26	service that has been provided following approval through the
27	preauthorization procedures provided by the insurer or which
28	have been disclosed as not subject to preauthorization
29	procedures shall not be subject to retrospective review or
30	concurrent review based on medical necessity related to the

- 32 -

1	preauthorization.
2	Section 2198. Data Collection and Reporting. (a) The
3	Insurance Department shall maintain and collect data on the
4	number of appeals filed by enrollees, enrollee designees and
5	health care providers with utilization review entities.
6	(b) The Insurance Department shall, on an annual basis,
7	publish a report made accessible on the department's publicly
8	accessible Internet website and serve a copy of the report on
9	the Banking and Insurance Committee of the Senate and the
10	Insurance Committee of the House of Representatives that
11	identifies the following data elements by place and type of
12	service:
13	(1) The total number of appeals filed against utilization
14	<u>review entities.</u>
15	(2) The number and percentage of appeals filed against each
16	utilization review entity.
17	(3) The total number of appeals found in favor of
18	utilization review entities.
19	(4) The number and percentage of appeals found in favor of
20	each managed care plan.
21	(5) The total number of appeals found in favor of the
22	enrollee, designee or health care provider.
23	(6) The number and percentage of appeals found in favor of
24	the enrollee, designee or health care provider against each
25	managed care plan.
26	(c) The Insurance Department shall evaluate, monitor and
27	track health plan statistics per the information gathered in
28	subsection (a) and investigate negative trends and outliers and
29	shall facilitate meetings between health care providers and
30	managed care plans to discuss and resolve disputes.

30 <u>managed care plans to discuss and resolve disputes.</u>

20210SB0225PN0948

1 Section 12. Nothing in this act shall be construed to

2 preclude an insurer from developing a program exempting a health-

<---

3 care provider from preauthorization protocols.

4 Section 13. This act shall take effect in 60 days.

5 SECTION 1. THE DEFINITIONS OF "EMERGENCY SERVICE," 6 "GRIEVANCE," "HEALTH CARE SERVICE," "PROSPECTIVE UTILIZATION 7 REVIEW," "RETROSPECTIVE UTILIZATION REVIEW," "UTILIZATION 8 REVIEW" AND "UTILIZATION REVIEW ENTITY" IN SECTION 2102 OF THE 9 ACT OF MAY 17, 1921 (P.L.682, NO.284), KNOWN AS THE INSURANCE 10 COMPANY LAW OF 1921, ARE AMENDED AND THE SECTION IS AMENDED BY 11 ADDING DEFINITIONS TO READ:

12 SECTION 2102. DEFINITIONS.--AS USED IN THIS ARTICLE, THE 13 FOLLOWING WORDS AND PHRASES SHALL HAVE THE MEANINGS GIVEN TO 14 THEM IN THIS SECTION:

15 \* \* \*

16 <u>"ADMINISTRATIVE DEFECT." ANY DEFICIENCY, ERROR, MISTAKE OR</u>
17 <u>MISSING INFORMATION OTHER THAN MEDICAL NECESSITY OR AN UNCOVERED</u>
18 <u>BENEFIT THAT SERVES AS THE BASIS OF AN ADVERSE DETERMINATION</u>
19 ISSUED BY A UTILIZATION REVIEW ENTITY AS JUSTIFICATION TO DENY

20 PRIOR UTILIZATION REVIEW OR PREAUTHORIZATION.

21 "ADVERSE DETERMINATION." THE FOLLOWING SHALL APPLY:

22 (1) A DECISION MADE BY A UTILIZATION REVIEW ENTITY FOLLOWING

23 <u>A PREAUTHORIZATION REQUEST THAT DENIES COVERAGE FOR ONE OR MORE</u>

- 24 THE FOLLOWING REASONS:
- 25 (I) THE HEALTH CARE SERVICE REQUESTED THROUGH

26 <u>PREAUTHORIZATION ARE NOT MEDICALLY NECESSARY.</u>

27 (II) THE PREAUTHORIZATION OR PRIOR UTILIZATION REVIEW

28 <u>REQUEST CONTAINS AN ADMINISTRATIVE DEFECT.</u>

29 (III) THE HEALTH CARE SERVICES REQUESTED THROUGH

30 PREAUTHORIZATION ARE SUBJECT TO THE BENEFIT COVERAGE OF A

20210SB0225PN0948

- 34 -

1	MANAGED CARE PLAN THAT HAS BEEN DENIED, MODIFIED OR TERMINATED
2	EITHER PRIOR TO THE REQUEST FOR PREAUTHORIZATION OR AS A RESULT
3	OF THE REQUESTED PREAUTHORIZATION.
4	(2) THE TERM INCLUDES A DECISION TO DENY A STEP THERAPY
5	EXCEPTION REQUEST UNDER SECTION 2118.
6	(3) THE TERM DOES NOT INCLUDE A DECISION TO DENY, REDUCE OR
7	TERMINATE SERVICES THAT ARE NOT COVERED FOR REASONS OTHER THAN
8	MEDICAL NECESSITY, EXPERIMENTAL OR INVESTIGATIONAL NATURE.
9	* * *
10	"AUTHORIZATION." A DETERMINATION BY A MANAGED CARE PLAN OR
11	UTILIZATION REVIEW ENTITY THAT:
12	(1) A HEALTH CARE SERVICE HAS BEEN REVIEWED AND, BASED ON
13	THE INFORMATION PROVIDED, IS MEDICALLY NECESSARY.
14	(2) THE HEALTH CARE SERVICE REVIEWED IS A COVERED SERVICE
15	UNDER THE PLAN.
16	(3) PAYMENT WILL BE MADE FOR THE HEALTH CARE SERVICE SUBJECT
17	TO COPAY, DEDUCTIBLE AND HEALTH CARE NETWORK RESTRICTIONS.
18	* * *
19	"CLINICAL CRITERIA." POLICIES, SCREENING PROCEDURES,
20	DETERMINATION RULES, DETERMINATION ABSTRACTS, CLINICAL
21	PROTOCOLS, PRACTICE GUIDELINES AND MEDICAL PROTOCOLS THAT ARE
22	SPECIFIED IN A WRITTEN DOCUMENT AVAILABLE FOR PEER-TO-PEER
23	REVIEW BY A PEER WITHIN THE SAME PROFESSION AND SPECIALTY AND
24	SUBJECT TO CHALLENGE BY AN ENROLLEE, A PROVIDER OR A PROVIDER
25	ORGANIZATION WHEN USED AS A BASIS TO WITHHOLD PREAUTHORIZATION,
26	DENY OR OTHERWISE MODIFY COVERAGE AND THAT IS USED BY A
27	UTILIZATION REVIEW ENTITY TO DETERMINE THE MEDICAL NECESSITY OF
28	HEALTH CARE SERVICES. THE CRITERIA SHALL:
29	(1) BE BASED ON NATIONALLY RECOGNIZED STANDARDS.
30	(2) BE DEVELOPED IN ACCORDANCE WITH THE CURRENT STANDARDS OF

1 NATIONAL ACCREDITATION ENTITIES.

2 (3) REFLECT COMMUNITY STANDARDS OF CARE.

3 (4) ENSURE QUALITY OF CARE AND ACCESS TO NEEDED HEALTH CARE 4 SERVICES.

5 (5) BE EVIDENCE-BASED OR BASED ON GENERALLY ACCEPTED EXPERT
6 CONSENSUS STANDARDS.

7 (6) BE SUFFICIENTLY FLEXIBLE TO ALLOW DEVIATIONS FROM THE

8 <u>STANDARDS WHEN JUSTIFIED ON A CASE-BY-CASE BASIS.</u>

9 (7) BE EVALUATED AND UPDATED ANNUALLY.

10 \* \* \*

"EMERGENCY SERVICE." ANY HEALTH CARE SERVICE PROVIDED TO AN 11 ENROLLEE, INCLUDING PREHOSPITAL TRANSPORTATION OR TREATMENT BY 12 13 EMERGENCY MEDICAL SERVICES PROVIDERS, AFTER THE SUDDEN ONSET OF A MEDICAL CONDITION THAT MANIFESTS ITSELF BY ACUTE SYMPTOMS OF 14 SUFFICIENT SEVERITY OR SEVERE PAIN SUCH THAT A PRUDENT LAYPERSON 15 16 WHO POSSESSES AN AVERAGE KNOWLEDGE OF HEALTH AND MEDICINE COULD REASONABLY EXPECT THE ABSENCE OF IMMEDIATE MEDICAL ATTENTION TO 17 18 RESULT IN:

19 (1) PLACING THE HEALTH OF THE ENROLLEE OR, WITH RESPECT TO A 20 PREGNANT WOMAN, THE HEALTH OF THE WOMAN OR HER UNBORN CHILD IN 21 SERIOUS JEOPARDY;

22 (2) SERIOUS IMPAIRMENT TO BODILY FUNCTIONS; OR

(3) SERIOUS DYSFUNCTION OF ANY BODILY ORGAN OR PART.
EMERGENCY TRANSPORTATION AND RELATED EMERGENCY SERVICE PROVIDED
BY A LICENSED AMBULANCE SERVICE SHALL CONSTITUTE AN EMERGENCY
SERVICE.

27 \* \* \*

28"FINAL ADVERSE DETERMINATION." AN ADVERSE DETERMINATION THAT29HAS BEEN UPHELD BY A UTILIZATION REVIEW ENTITY OR MANAGED CARE

30 PLAN AT THE COMPLETION OF THE INTERNAL GRIEVANCE PROCESS.

20210SB0225PN0948

- 36 -

"GRIEVANCE." AS PROVIDED IN SUBDIVISION (I), A REQUEST BY AN
ENROLLEE OR A HEALTH CARE PROVIDER, WITH THE WRITTEN CONSENT OF
THE ENROLLEE, TO HAVE A MANAGED CARE PLAN OR UTILIZATION REVIEW
ENTITY RECONSIDER A DECISION SOLELY CONCERNING THE MEDICAL
NECESSITY [AND APPROPRIATENESS] OF A HEALTH CARE SERVICE. IF THE
MANAGED CARE PLAN IS UNABLE TO RESOLVE THE MATTER, A GRIEVANCE
MAY BE FILED REGARDING THE DECISION THAT:

8 (1) DISAPPROVES FULL OR PARTIAL PAYMENT FOR A REQUESTED9 HEALTH CARE SERVICE;

10 (2) APPROVES THE PROVISION OF A REQUESTED HEALTH CARE
11 SERVICE FOR A LESSER SCOPE OR DURATION THAN REQUESTED; OR
12 (3) DISAPPROVES PAYMENT FOR THE PROVISION OF A REQUESTED
13 HEALTH CARE SERVICE BUT APPROVES PAYMENT FOR THE PROVISION OF AN

14 ALTERNATIVE HEALTH CARE SERVICE.

15 THE TERM DOES NOT INCLUDE A COMPLAINT.

16 \* \* \*

"HEALTH CARE SERVICE." ANY [COVERED] TREATMENT, ADMISSION,
PROCEDURE, <u>TEST USED TO AID IN DIAGNOSIS OR THE PROVISIONS OF</u>
<u>THE APPLICABLE TREATMENT, PHARMACEUTICAL PRODUCT, MEDICAL</u>
SUPPLIES AND EQUIPMENT OR OTHER SERVICES, INCLUDING BEHAVIORAL
HEALTH[, PRESCRIBED OR OTHERWISE] PROVIDED OR PROPOSED TO BE
PROVIDED BY A HEALTH CARE PROVIDER TO AN ENROLLEE UNDER A
MANAGED CARE PLAN CONTRACT.

24 \* \* \*

25 <u>"MEDICALLY NECESSARY HEALTH CARE SERVICES" OR "MEDICALLY</u>
26 <u>NECESSARY." HEALTH CARE SERVICES THAT A PRUDENT HEALTH CARE</u>
27 <u>PROVIDER WOULD PROVIDE TO A PATIENT FOR THE PURPOSE OF</u>
28 <u>PREVENTING, DIAGNOSING OR TREATING AN ILLNESS, INJURY, DISEASE</u>
29 <u>OR ITS SYMPTOMS IN A MANNER THAT MEETS ALL THE FOLLOWING:</u>
30 (1) IN ACCORDANCE WITH GENERALLY ACCEPTED STANDARDS OF

20210SB0225PN0948

- 37 -

1 MEDICAL PRACTICE BASED ON CLINICAL CRITERIA.

2 (2) APPROPRIATE IN TERMS OF TYPE, FREQUENCY, EXTENT, SITE
 3 AND DURATION IN ACCORDANCE WITH CLINICAL CRITERIA.

4 <u>"NONURGENT HEALTH CARE SERVICE." A HEALTH CARE SERVICE</u>

5 PROVIDED TO AN ENROLLEE THAT IS NOT CONSIDERED AN EMERGENCY

6 <u>SERVICE OR AN URGENT HEALTH CARE SERVICE.</u>

7 \* \* \*

8 "PROSPECTIVE UTILIZATION REVIEW[.]," "PREAUTHORIZATION" OR 9 "PRIOR AUTHORIZATION." A REVIEW BY A UTILIZATION REVIEW ENTITY 10 OF ALL REASONABLY NECESSARY SUPPORTING INFORMATION THAT OCCURS 11 PRIOR TO THE DELIVERY OR PROVISION OF A HEALTH CARE SERVICE AND 12 RESULTS IN A DECISION TO APPROVE OR DENY PAYMENT FOR THE HEALTH 13 CARE SERVICE.

14 \* \* \*

15 "RETROSPECTIVE UTILIZATION REVIEW[.]" <u>OR "RETROSPECTIVE</u>
16 <u>REVIEW."</u> A REVIEW BY A UTILIZATION REVIEW ENTITY OF ALL
17 REASONABLY NECESSARY SUPPORTING INFORMATION WHICH OCCURS
18 FOLLOWING DELIVERY OR PROVISION OF A HEALTH CARE SERVICE AND
19 RESULTS IN A DECISION TO APPROVE OR DENY PAYMENT FOR THE HEALTH
20 CARE SERVICE.

21 \* \* \*

22 <u>"URGENT HEALTH CARE SERVICE." THE FOLLOWING SHALL APPLY:</u>

23 (1) A HEALTH CARE SERVICE DEEMED BY A PROVIDER TO REQUIRE

24 EXPEDITED PREAUTHORIZATION REVIEW IN THE EVENT A DELAY MAY

25 JEOPARDIZE LIFE OR HEALTH OF THE ENROLLEE OR A DELAY IN

26 TREATMENT COULD DO ANY OF THE FOLLOWING:

27 (I) NEGATIVELY AFFECT THE ABILITY OF THE ENROLLEE TO REGAIN

28 MAXIMUM FUNCTION.

29 (II) SUBJECT THE ENROLLEE TO SEVERE PAIN THAT CANNOT BE

30 ADEQUATELY MANAGED WITHOUT RECEIVING THE CARE OR TREATMENT THAT

20210SB0225PN0948

- 38 -

1 IS THE SUBJECT OF THE UTILIZATION REVIEW AS QUICKLY AS POSSIBLE.

2 (2) THE TERM DOES NOT INCLUDE AN EMERGENCY SERVICE OR

3 NONURGENT HEALTH CARE SERVICE.

4 "UTILIZATION REVIEW." A SYSTEM OF PROSPECTIVE, CONCURRENT OR
5 RETROSPECTIVE UTILIZATION REVIEW PERFORMED BY A UTILIZATION
6 REVIEW ENTITY OF THE MEDICAL NECESSITY [AND APPROPRIATENESS] OF
7 HEALTH CARE SERVICES PRESCRIBED, PROVIDED OR PROPOSED TO BE
8 PROVIDED TO AN ENROLLEE. THE TERM DOES NOT INCLUDE ANY OF THE
9 FOLLOWING:

10 (1) REQUESTS FOR CLARIFICATION OF COVERAGE, ELIGIBILITY OR11 HEALTH CARE SERVICE VERIFICATION.

12 (2) A HEALTH CARE PROVIDER'S INTERNAL QUALITY ASSURANCE OR 13 UTILIZATION REVIEW PROCESS UNLESS THE REVIEW RESULTS IN DENIAL 14 OF PAYMENT FOR A HEALTH CARE SERVICE.

15 "UTILIZATION REVIEW ENTITY." ANY ENTITY CERTIFIED PURSUANT 16 TO SUBDIVISION (H) THAT PERFORMS UTILIZATION REVIEW ON BEHALF OF 17 A MANAGED CARE PLAN. <u>THE TERM INCLUDES ALL THE FOLLOWING:</u>

18 (1) AN INSURER THAT WRITES HEALTH INSURANCE POLICIES,

19 <u>INCLUDING PREFERRED PROVIDER ORGANIZATIONS AS DEFINED IN SECTION</u> 20 630.

21 (2) PHARMACY BENEFITS MANAGERS RESPONSIBLE FOR MANAGING

22 ACCESS OF ENROLLEES TO AVAILABLE PHARMACEUTICAL OR

23 PHARMACOLOGICAL CARE.

24 (3) A HEALTH INSURER IF THE HEALTH INSURERE PERFORMS

25 <u>UTILIZATION REVIEW.</u>

26 SECTION 2. SECTION 2111(3) OF THE ACT IS AMENDED AND THE 27 SECTION IS AMENDED BY ADDING PARAGRAPHS TO READ:

28 SECTION 2111. RESPONSIBILITIES OF MANAGED CARE PLANS.--A 29 MANAGED CARE PLAN SHALL DO ALL OF THE FOLLOWING:

30 \* \* \*

20210SB0225PN0948

- 39 -

1	(3) [ADOPT AND MAINTAIN A DEFINITION OF MEDICAL NECESSITY
2	USED BY THE PLAN IN DETERMINING HEALTH CARE SERVICES.]
3	ESTABLISH AN ELECTRONIC PLATFORM AND PROCESS FOR THE SUBMISSION
4	AND RECEIPT OF PRIOR AUTHORIZATION REQUESTS BY NETWORK
5	PROVIDERS. THE FOLLOWING SHALL APPLY:
6	(I) EACH MANAGED CARE PLAN MUST PROVIDE WRITTEN INSTRUCTIONS
7	AND TRAINING TO NETWORK PROVIDERS WHO MAY SUBMIT REQUESTS USING
8	THE ELECTRONIC PLATFORM THAT SET FORTH PROTOCOLS ADDRESSING
9	SUBMISSION OF PREAUTHORIZATION REQUESTS IF ANY OF THE FOLLOWING
10	APPLY:
11	(A) THE ELECTRONIC PLATFORM IS NOT AVAILABLE DUE TO
12	TECHNOLOGICAL FAILURE OR ELECTRONIC FAILURE.
13	(B) DOCUMENTS REQUESTED BY THE MANAGED CARE PLAN OR
14	UTILIZATION REVIEW ENTITY EXCEED THE SUBMISSION CAPACITY
15	LIMITATIONS OF THE ELECTRONIC PLATFORM.
16	(II) EACH MANAGED HEALTH CARE PLAN SHALL ESTABLISH MUTUALLY
17	AGREEABLE TERMS FOR SUBMISSION OF PREAUTHORIZATION REQUESTS AND
18	COMMUNICATION REGARDING PREAUTHORIZATION IN CIRCUMSTANCES WHERE
19	A NETWORK PROVIDER OR HEALTH CARE FACILITY DOES NOT HAVE EITHER
20	OF THE FOLLOWING:
21	(A) INTERNET ACCESS.
22	(B) AN ELECTRONIC HEALTH RECORD SYSTEMS.
23	* * *
24	(14) PUBLISH AVAILABLE HEALTH CARE SERVICES SUBJECT TO PRIOR
25	AUTHORIZATION ON ITS PUBLICLY ACCESSIBLE INTERNET WEBSITE IN AN
26	EASILY ACCESSIBLE MANNER AND SHALL PROVIDE THE INFORMATION UPON
27	REQUEST OF A PARTICIPATING NETWORK PROVIDER.
28	(15) PROVIDE SIXTY (60) DAYS NOTICE TO PARTICIPATING NETWORK
29	PROVIDERS OF ANY CHANGES TO EXISTING PRIOR AUTHORIZATION
30	CRITERIA OR IMPLEMENTATION OF NEW PRIOR AUTHORIZATION

- 40 -

1 <u>REQUIREMENTS.</u>

2	(16) ESTABLISH A PROTOCOL TO OBTAIN AN EXCEPTION FROM ANY
3	STEP THERAPY REQUIREMENTS AND PUBLISH THAT PROCESS IN AN EASILY
4	ACCESSIBLE MANNER ON ITS PUBLICLY ACCESSIBLE INTERNET WEBSITE.
5	(17) PROVIDE THE RULES AND CRITERIA RELATED TO THE STEP
6	THERAPY PROTOCOL UPON REQUEST TO ALL PRESCRIBING NETWORK
7	PROVIDERS.
8	SECTION 3. THE ACT IS AMENDED BY ADDING SECTIONS TO READ:
9	SECTION 2114. PREAUTHORIZATION REVIEW STANDARDS(A)
10	PREAUTHORIZATION APPROVAL REQUESTS MAY BE SUBMITTED
11	ELECTRONICALLY THROUGH A SECURE ELECTRONIC TRANSMISSION PLATFORM
12	ESTABLISHED AND MAINTAINED BY A MANAGED CARE PLAN UNDER SECTION
13	2111(3). AN ELECTRONIC SUBMISSION SHALL NOT BE REQUIRED IN
14	CIRCUMSTANCES WHERE THE MANAGED CARE PLAN HAS NOT PUBLISHED
15	PROTOCOLS OR PROVIDED TRAINING AS REQUIRED BY SECTION 2111(3).
16	(B) ANY RESTRICTION THAT A UTILIZATION REVIEW ENTITY PLACES
17	ON THE PREAUTHORIZATION OF HEALTH CARE SERVICES SHALL BE IN
18	ACCORDANCE WITH THE FOLLOWING:
19	(1) BASED ON THE MEDICAL NECESSITY OF THOSE SERVICES AND ON
20	ANY ADDITIONAL CLINICAL CRITERIA INFORMATION SUBMITTED BY THE
21	PROVIDER SEEKING AUTHORIZATION OF THE HEALTH CARE SERVICE ON
22	BEHALF OF THE ENROLLEE.
23	(2) APPLIED CONSISTENTLY.
24	(3) DISCLOSED BY THE MANAGED CARE PLAN OR UTILIZATION REVIEW
25	ENTITY UNDER SECTIONS 2111 AND 2136.
26	(C) ADVERSE DETERMINATIONS AND FINAL ADVERSE DETERMINATIONS
27	MADE BY A UTILIZATION REVIEW ENTITY OR AGENT THEREOF SHALL BE
28	BASED ON MEDICAL NECESSITY AND SUPPORTING CLINICAL CRITERIA
29	SUBMITTED BY THE PROVIDER SEEKING AUTHORIZATION FOR THE HEALTH
30	CARE SERVICE ON BEHALF OF THE ENROLLEE.

20210SB0225PN0948

- 41 -

1	(D) A UTILIZATION REVIEW ENTITY SHALL NOT DENY COVERAGE OF A
2	HEALTH CARE SERVICE SOLELY BASED ON THE GROUNDS THAT THE HEALTH
3	CARE SERVICE DOES NOT MEET CLINICAL CRITERIA.
4	(E) PREAUTHORIZATION SHALL NOT BE REQUIRED IN ANY OF THE
5	FOLLOWING:
6	(1) IF A PRESCRIBED MEDICATION IS A NONCONTROLLED GENERIC
7	MEDICATION.
8	(2) IF A PROCEDURE TO BE PERFORMED IS CUSTOMARY AND PROPERLY
9	INDICATED OR IS A TREATMENT FOR THE CLINICAL INDICATION AS
10	SUPPORTED BY PEER-REVIEWED MEDICAL PUBLICATIONS.
11	(3) FOR THE PROVISION OF MAT FOR THE TREATMENT OF AN OPIOID-
12	USE DISORDER.
13	(F) IF A PROVIDER CONTACTS A UTILIZATION REVIEW ENTITY
14	SEEKING PREAUTHORIZATION FOR A MEDICALLY NECESSARY HEALTH CARE
15	SERVICE UNDER SECTION 2111(14) AND THE UTILIZATION REVIEW
16	ENTITY, THROUGH AN AGENT, CONTRACTOR, EMPLOYE OR REPRESENTATIVE
17	INFORMS THE PROVIDER THAT PREAUTHORIZATION IS NOT REQUIRED FOR
18	THE HEALTH CARE SERVICE SUBJECT TO THE REQUEST, COVERAGE FOR THE
19	SERVICE SHALL BE DEEMED APPROVED.
20	SECTION 2115. PREAUTHORIZATION COSTS(A) IN THE EVENT
21	THAT AN INSURED IS COVERED BY MORE THAN ONE HEALTH PLAN THAT
22	REQUIRES PREAUTHORIZATION:
23	(1) A SECONDARY MANAGED HEALTH CARE PLAN SHALL NOT DENY
24	PREAUTHORIZATION FOR A HEALTH CARE SERVICE SOLELY ON THE BASIS
25	THAT THE PREAUTHORIZATION PROCEDURES OF THE SECONDARY INSURER
26	WERE NOT FOLLOWED IF THE ENROLLEE SUBJECT TO THE PLAN RECEIVED
27	PREAUTHORIZATION FROM THE ENROLLEE'S PRIMARY MANAGED HEALTH CARE
28	PLAN.
29	(2) NOTHING IN THIS SECTION SHALL BE CONSTRUED TO PRECLUDE A
30	SECONDARY INSURER FROM REQUIRING PREAUTHORIZATION FOR A HEALTH

- 42 -

1	CARE SERVICE DENIED PREAUTHORIZATION BY A PRIMARY INSURER.
2	(B) ANY INTERNAL GRIEVANCE OR INTERNAL REVIEW OF AN ADVERSE
3	DETERMINATION OF A FINAL ADVERSE DETERMINATION SHALL BE PROVIDED
4	WITHOUT CHARGE TO THE ENROLLEE OR ENROLLEE'S HEALTH CARE
5	PROVIDER.
6	SECTION 4. SECTION 2117 OF THE ACT IS AMENDED BY ADDING
7	SUBSECTIONS TO READ:
8	SECTION 2117. CONTINUITY OF CARE* * *
9	(G) IF THE APPEAL OF AN ADVERSE DETERMINATION FROM A
10	PREAUTHORIZATION REQUEST CONCERNS ONGOING HEALTH CARE SERVICES
11	PROVIDED UNDER AN INITIALLY AUTHORIZED ADMISSION OR COURSE OF
12	TREATMENT, THE HEALTH CARE SERVICES SHALL CONTINUE TO BE
13	PROVIDED TO THE ENROLLEE AND PAID FOR BY THE MANAGED CARE PLAN
14	WITHOUT LIABILITY TO THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE
15	PROVIDER FOR NO LESS THAN SIXTY (60) DAYS.
16	(H) THE MANAGED CARE PLAN OR UTILIZATION REVIEW ENTITY SHALL
17	NOT BE PERMITTED TO RETROACTIVELY REVIEW THE DECISION TO
18	AUTHORIZE AND PROVIDE HEALTH CARE SERVICES THROUGH
19	PREAUTHORIZATION, INCLUDING PREAUTHORIZATION FOR EXTENDING THE
20	TERM OR COURSE OF TREATMENT UNLESS THE MANAGED CARE PLAN OR
21	UTILIZATION REVIEW ENTITY CAN DEMONSTRATE BY CLEAR AND
22	CONVINCING EVIDENCE THAT PREAUTHORIZATION WAS AUTHORIZED USING
23	KNOWINGLY INACCURATE CLINICAL INFORMATION SUBMITTED BY THE
24	PROVIDER OR FRAUD.
25	(I) NOTWITHSTANDING ANY OTHER PROVISION OF LAW, THE MANAGED
26	CARE PLAN SHALL NOT RETROACTIVELY RECOVER THE COST OF TREATMENT
27	EITHER FOR THE INITIAL PERIOD OF TREATMENT SUBJECT TO
28	PREAUTHORIZATION OR THE PERIOD OF TREATMENT PROVIDED TO THE
29	ENROLLEE AS PART OF THE PREAUTHORIZATION DECISION-MAKING PROCESS
30	TO AUTHORIZE COVERAGE OF ADDITIONAL TREATMENT PERIODS.

- 43 -

1	(J) CONTINUED CARE SHALL NOT BE SUBJECT TO CONCURRENT REVIEW
2	IF THE TREATMENT REGIMEN OR CONTINUITY OF CARE FOLLOWS FROM A
3	AUTHORIZING PREVIOUS PREAUTHORIZATION REQUEST UNLESS THE MANAGED
4	CARE PLAN OR UTILIZATION REVIEW ENTITY CAN DEMONSTRATE BY CLEAR
5	AND CONVINCING EVIDENCE THAT PREAUTHORIZATION WAS AUTHORIZED
6	USING KNOWINGLY INACCURATE CLINICAL INFORMATION SUBMITTED BY THE
7	PROVIDER OR FRAUD.
8	SECTION 5. THE ACT IS AMENDED BY ADDING A SECTION TO READ:
9	SECTION 2118. STEP THERAPY(A) (1) WHEN COVERAGE OF A
10	PRESCRIPTION DRUG FOR THE TREATMENT OF ANY MEDICAL CONDITION IS
11	RESTRICTED FOR USE BY A MANAGED CARE PLAN OR UTILIZATION REVIEW
12	ENTITY THROUGH A STEP THERAPY PROTOCOL, THE ENROLLEE AND
13	PROVIDER SHALL HAVE ACCESS TO A CLEAR, READILY ACCESSIBLE AND
14	CONVENIENT PROCESS TO REQUEST A STEP THERAPY EXCEPTION UNDER
15	SECTION 2111(16). FAILURE OF THE MANAGED CARE PLAN TO MEET ITS
16	OBLIGATION UNDER SECTION 2111 SHALL RESULT IN ALL STEP THERAPY
17	EXCEPTIONS BEING DEEMED APPROVED UNTIL THE MANAGED CARE PLAN
18	COMPLIES WITH THE REQUIREMENTS OF SECTION 2111(16).
19	(2) NO STEP THERAPY SHALL BE REQUIRED IF THE MEDICATION
20	BEING PRESCRIBED IS BEING PRESCRIBED IN RESPONSE TO AN
21	EMERGENCY.
22	(3) A STEP THERAPY EXCEPTION SHALL BE GRANTED IF ANY OF THE
23	FOLLOWING APPLY:
24	(I) THE REQUIRED PRESCRIPTION DRUG IS CONTRAINDICATED, NOT
25	IN THE BEST INTEREST OF THE ENROLLEE OR WILL LIKELY CAUSE AN
26	ADVERSE REACTION BY OR PHYSICAL OR MENTAL HARM TO THE ENROLLEE.
27	(II) THE REQUIRED PRESCRIPTION DRUG IS EXPECTED TO BE
28	INEFFECTIVE BASED ON THE KNOWN CLINICAL CHARACTERISTICS OF THE
29	ENROLLEE AND THE KNOWN CHARACTERISTICS OF THE PRESCRIPTION DRUG
30	REGIMEN.

- 44 -

1	(III) THE ENROLLEE HAS TRIED THE REQUIRED PRESCRIPTION DRUG
2	WHILE UNDER THE ENROLLEE'S CURRENT OR PREVIOUS HEALTH CARE PLAN
3	OR HEALTH BENEFIT PLAN, OR ANOTHER PRESCRIPTION DRUG IN THE SAME
4	PHARMACOLOGIC CLASS OR WITH THE SAME MECHANISM OF ACTION, AND
5	THE PRESCRIPTION DRUG WAS DISCONTINUED DUE TO LACK OF EFFICACY
6	OR EFFECTIVENESS, DIMINISHED EFFECT OR AN ADVERSE EVENT.
7	(IV) THE ENROLLEE IS STABLE ON A PRESCRIPTION DRUG
8	PREVIOUSLY SELECTED BY THE ENROLLEE'S PROVIDER AND PREVIOUSLY
9	APPROVED BY A MANAGED CARE PLAN OR UTILIZATION REVIEW ENTITY.
10	(4) GRANTING THE STEP THERAPY EXCEPTION SHALL AUTHORIZE
11	COVERAGE FOR THE PRESCRIPTION DRUG PRESCRIBED BY THE ENROLLEE'S
12	TREATING HEALTH CARE PROVIDER.
13	(B) STEP THERAPY EXCEPTION REQUESTS OR AN APPEAL THEREOF
14	SHALL BE GRANTED OR DENIED WITHIN FIVE (5) BUSINESS DAYS OF
15	RECEIPT, SUBJECT TO THE FOLLOWING:
16	(1) IN CASES WHERE THE REQUESTED EXCEPTION IS RELATED TO AN
17	URGENT HEALTHCARE TREATMENT, THE MANAGED CARE PLAN OR
18	UTILIZATION REVIEW ENTITY EVALUATING THE EXCEPTION SHALL RESPOND
19	WITHIN TWENTY-FOUR (24) HOURS OF RECEIPT OF THE REQUEST.
20	(2) IF A REQUEST FOR AN EXCEPTION UNDER THIS SECTION IS
21	INCOMPLETE OR ADDITIONAL CLINICALLY RELEVANT INFORMATION IS
22	REQUIRED, THE MANAGED CARE PLAN OR UTILIZATION REVIEW ENTITY
23	SHALL NOTIFY THE PRESCRIBING PRACTITIONER WITHIN FIVE (5)
24	BUSINESS DAYS OF SUBMISSION, OR TWENTY-FOUR (24) HOURS IN AN
25	URGENT HEALTH CARE REQUEST, THAT ADDITIONAL OR CLINICALLY
26	RELEVANT INFORMATION IS REQUIRED IN ORDER TO APPROVE OR DENY THE
27	STEP THERAPY EXCEPTION REQUEST OR APPEAL UNDER THIS SECTION. THE
28	REQUEST FOR ADDITIONAL INFORMATION MAY ONLY EXTEND THE DEADLINES
29	HEREIN AN ADDITIONAL FORTY-EIGHT (48) HOURS FOR NONURGENT
30	HEALTHCARE SERVICES SUBJECT TO STEP THERAPY.

(C) IF A DETERMINATION IS NOT RENDERED WITHIN THE APPLICABLE 1 2 DEADLINES, THE REQUESTED EXCEPTION SHALL BE DEEMED APPROVED, AND TREATMENT AUTHORIZED. IN A CIRCUMSTANCE WHERE THE EXCEPTION HAS 3 BEEN DEEMED APPROVED AND TREATMENT HAS BEEN AUTHORIZED SHALL NOT 4 BE SUBJECT TO CONCURRENT REVIEW OR RETROACTIVE REVIEW BECAUSE OF 5 THE FAILURE OF THE MANAGED CARE PLAN TO RENDER A DETERMINATION 6 7 UNDER THIS SECTION. 8 (D) IN THE EVENT OF A DENIAL, THE MANAGED CARE PLAN OR 9 UTILIZATION REVIEW ENTITY SHALL INFORM THE ENROLLEE OF THE RIGHT TO A GRIEVANCE PROCESS. THIS SUBSECTION SHALL NOT BE CONSTRUED 10 11 TO PREVENT: 12 (1) A MANAGED CARE PLAN OR UTILIZATION REVIEW ENTITY FROM 13 REOUIRING A PHARMACIST TO EFFECT SUBSTITUTIONS OF PRESCRIPTION DRUGS CONSISTENT WITH THE LAWS OF THIS COMMONWEALTH. 14 15 (2) A HEALTH CARE PROVIDER FROM PRESCRIBING A PRESCRIPTION DRUG THAT IS DETERMINED TO BE MEDICALLY APPROPRIATE. 16 17 (E) AS USED IN THIS SECTION, THE FOLLOWING WORDS AND PHRASES 18 SHALL HAVE THE MEANINGS GIVEN TO THEM IN THIS SECTION: 19 "STEP THERAPY EXCEPTION." WHEN A STEP THERAPY PROTOCOL SHOULD BE OVERRIDDEN IN FAVOR OF IMMEDIATE COVERAGE OF THE 20 HEALTH CARE PROVIDER'S SELECTED PRESCRIPTION DRUG. 21 "STEP THERAPY PROTOCOL." A PROTOCOL, POLICY OR PROGRAM THAT 22 23 ESTABLISHES THE SPECIFIC SEQUENCE IN WHICH PRESCRIPTION DRUGS 24 FOR A SPECIFIED MEDICAL CONDITION AND MEDICALLY APPROPRIATE FOR 25 A PARTICULAR PATIENT ARE COVERED BY AN INSURER OR HEALTH PLAN. 26 SECTION 6. ARTICLE XXI, SUBDIVISION (F) HEADING OF THE ACT 27 IS AMENDED TO READ: 28 (F) INFORMATION FOR ENROLLEES AND HEALTH CARE PROVIDERS. 29 SECTION 7. SECTION 2136 OF THE ACT IS AMENDED BY ADDING A 30 SUBSECTION TO READ:

20210SB0225PN0948

- 46 -

1 SECTION 2136. REQUIRED DISCLOSURE.--\* \* \*

2 (C) IF EITHER A MANAGED CARE PLAN OR UTILIZATION REVIEW

3 ENTITY INTENDS TO IMPLEMENT A NEW PREAUTHORIZATION REQUIREMENT

4 OR RESTRICTION OR AMEND AN EXISTING REQUIREMENT OR RESTRICTION,

5 THE MANAGED CARE PLAN OR UTILIZATION REVIEW ENTITY SHALL PROVIDE

6 <u>NETWORK PROVIDERS AND ENROLLEES WITH WRITTEN NOTICE OF THE NEW</u>

7 OR AMENDED REQUIREMENT OR AMENDMENT NOT LESS THAN SIXTY (60)

8 DAYS BEFORE IMPLEMENTATION. THE NOTICE SHALL BE IN WRITING WHICH

9 MAY BE SATISFIED BY ANY OF THE FOLLOWING:

10 (1) MAIL THROUGH THE UNITED STATES POSTAL SERVICE.

11 (2) ELECTRONIC MAIL READ RECEIPT REQUESTED.

12 (3) PUBLICATION ON THE PUBLICLY ACCESSIBLE INTERNET WEBSITE

13 OF THE MANAGED CARE PLAN OR UTILIZATION REVIEW ENTITY WITH AN

14 ELECTRONIC MAIL MESSAGE TO NETWORK PROVIDERS AND ENROLLEES THAT

15 IDENTIFIES THE LOCATION OF THE PUBLICATION ON THE WEBSITE.

16 (4) WEB-EXCHANGE, PROVIDED THAT AN ELECTRONIC MAIL MESSAGE

17 ON HOW TO ACCESS THE WEB-EXCHANGE IS SENT TO NETWORK PROVIDERS

18 AND ENROLLEES.

19 (5) ANY OTHER CONTRACTUALLY AGREED UPON METHOD, SPECIFYING

20 THE DETAILS OF THE COMMUNICATION WHICH INCLUDE SOME PROOF OF

21 RECEIPT BY THE NETWORK PROVIDERS AND ENROLLEES.

22 SECTION 8. SECTION 2152(A)(4) AND (6) OF THE ACT ARE 23 AMENDED, SUBSECTION (A) IS AMENDED BY ADDING PARAGRAPHS AND THE 24 SECTION IS AMENDED BY ADDING A SUBSECTION TO READ:

25 SECTION 2152. OPERATIONAL STANDARDS.--(A) A UTILIZATION 26 REVIEW ENTITY SHALL DO ALL OF THE FOLLOWING:

27 \* \* \*

(4) CONDUCT UTILIZATION REVIEWS BASED ON THE MEDICAL
NECESSITY [AND APPROPRIATENESS] OF THE HEALTH CARE SERVICE BEING
REVIEWED AND PROVIDE NOTIFICATION WITHIN THE FOLLOWING TIME

20210SB0225PN0948

- 47 -

1 FRAMES:

2 A PROSPECTIVE UTILIZATION REVIEW DECISION SHALL BE (I) 3 COMMUNICATED WITHIN TWO (2) BUSINESS DAYS OF THE RECEIPT OF ALL 4 SUPPORTING INFORMATION REASONABLY NECESSARY TO COMPLETE THE 5 REVIEW.] A PROSPECTIVE UTILIZATION REVIEW OR PREAUTHORIZATION DECISION SHALL BE RENDERED NOT MORE THAN SEVEN (7) DAYS AFTER 6 7 INITIAL SUBMISSION OF THE REQUEST FOR AUTHORIZATION. THE 8 DECISION TO AUTHORIZE OR DENY THE REQUESTED HEALTH CARE SERVICE 9 SHALL BE COMMUNICATED WITHIN FIVE (5) BUSINESS DAYS OF THE 10 RECEIPT OF ALL SUPPORTING INFORMATION REASONABLY NECESSARY TO COMPLETE THE REVIEW. IF THE INITIAL SUBMISSION DOES NOT CONTAIN 11 ALL OF THE SUPPORTING INFORMATION REASONABLY NECESSARY TO 12 13 COMPLETE THE REVIEW, THE UTILIZATION REVIEW ENTITY MAY REQUEST ADDITIONAL INFORMATION FROM THE PROVIDER BUT THE REQUEST SHALL 14 ONLY EXTEND THE SEVEN (7) DAY DEADLINE FOR A DECISION EITHER 15 AUTHORIZING OR DENYING THE HEALTH CARE SERVICE AN ADDITIONAL 16 17 FORTY-EIGHT (48) HOURS. 18 (II) A CONCURRENT UTILIZATION REVIEW DECISION SHALL BE 19 COMMUNICATED WITHIN ONE (1) BUSINESS DAY OF THE RECEIPT OF ALL 20 SUPPORTING INFORMATION REASONABLY NECESSARY TO COMPLETE THE 21 REVIEW. (III) A RETROSPECTIVE UTILIZATION REVIEW DECISION SHALL BE 22 23 COMMUNICATED WITHIN THIRTY (30) DAYS OF THE RECEIPT OF ALL 24 SUPPORTING INFORMATION REASONABLY NECESSARY TO COMPLETE THE 25 REVIEW. UTILIZATION REVIEW ENTITIES SHALL NOT RETROACTIVELY 26 REVIEW THE MEDICAL NECESSITY OF A PREAUTHORIZATION THAT HAS BEEN 27 PREVIOUSLY APPROVED OR GRANTED UNDER SECTION 2117. 28 (IV) A UTILIZATION REVIEW ENTITY SHALL ALLOW AN ENROLLEE AND 29 THE ENROLLEE'S HEALTH CARE PROVIDER A MINIMUM OF ONE (1) BUSINESS DAY FOLLOWING AN INPATIENT ADMISSION UNDER EMERGENCY 30

- 48 -

HEALTH CARE SERVICE OR URGENT HEALTH CARE SERVICE TO NOTIFY THE 1 2 UTILIZATION REVIEW ENTITY OF THE ADMISSION AND ANY HEALTH CARE 3 SERVICES PERFORMED. \* \* \* 4 5 (6) PROVIDE ALL DECISIONS IN WRITING TO INCLUDE THE BASIS AND CLINICAL RATIONALE FOR THE DECISION. FOR ADVERSE 6 7 DETERMINATIONS FROM PREAUTHORIZATION REQUESTS, A UTILIZATION 8 REVIEW ENTITY SHALL PROVIDE NOTICE OF ALL ADVERSE DETERMINATIONS 9 TO THE ENROLLEE AND THE ENROLLEE'S HEALTH CARE PROVIDER. THE 10 NOTICE OF ADVERSE DETERMINATION SHALL INCLUDE INSTRUCTIONS CONCERNING HOW A GRIEVANCE MAY BE FILED FOR AN ADVERSE 11 12 DETERMINATION BASED ON MEDICAL NECESSITY. IF THE ADVERSE 13 DETERMINATION IS BASED ON AN ADMINISTRATIVE DEFECT, THE DETERMINATION SHALL PROVIDE INFORMATION ON HOW THE DEFECT MAY BE 14 CURED AND INSTRUCTIONS FOR RESUBMITTING THE PREAUTHORIZATION 15 16 REOUEST. \* \* \* 17 18 (9) POST THE FOLLOWING TO THE UTILIZATION REVIEW ENTITY'S 19 PUBLICLY ACCESSIBLE INTERNET WEBSITE: (I) A CURRENT LIST OF SERVICES AND SUPPLIES REQUIRING 20 21 PREAUTHORIZATION. 22 (II) WRITTEN CLINICAL CRITERIA FOR PREAUTHORIZATION 23 DECISIONS. 24 (10) ENSURE THAT A PREAUTHORIZATION SHALL BE VALID FOR NO 25 LONGER THAN ONE HUNDRED EIGHTY (180) DAYS OR THE DURATION OF 26 TREATMENT, WHICHEVER IS GREATER, FROM THE DATE THE HEALTH CARE 27 PROVIDER RECEIVES THE PREAUTHORIZATION SO LONG AS THE ENROLLEE 28 IS A MEMBER OF THE PLAN. 29 (11) WHEN PERFORMING PREAUTHORIZATION, ONLY REQUEST COPIES OF MEDICAL RECORDS RELEVANT TO DETERMINING THE MEDICAL NECESSITY 30

20210SB0225PN0948

- 49 -

1 OF A HEALTH CARE SERVICE REQUESTED.

2	(12) IN THE EVENT AN ADMINISTRATIVE DEFECT IS DISCOVERED, A
3	MANAGED CARE PLAN SHALL ALLOW A HEALTH CARE PROVIDER THE
4	OPPORTUNITY TO REMEDY THE ADMINISTRATIVE DEFECT WITHIN FORTY-
5	EIGHT HOURS (48) HOURS OF RECEIVING NOTICE OF THE DEFECT. IF A
6	HEALTH CARE PROVIDER REMEDIES THE ADMINISTRATIVE DEFECT, A
7	DETERMINATION OF PREAUTHORIZATION SHALL BE RENDERED WITHIN
8	FORTY-EIGHT (48) HOURS. IF THE ADMINISTRATIVE DEFECT REMAINS
9	UNCURED, THE MANAGED CARE PLAN MAY DENY PREAUTHORIZATION.
10	* * *
11	(E) FAILURE BY A UTILIZATION REVIEW ENTITY TO COMPLY WITH
12	DEADLINES AND OTHER REQUIREMENTS SPECIFIED FOR PREAUTHORIZATION
13	SHALL RESULT IN THE REQUESTED PREAUTHORIZATION FOR THE HEALTH
14	CARE SERVICE TO BE DEEMED AUTHORIZED AND PAID BY THE MANAGED
15	CARE PLAN. FAILURE OF THE PROVIDER CURE ANY ADMINISTRATIVE
16	DEFECTS IN PREAUTHORIZATION REQUESTS IN A TIMELY MANNER UNDER
17	THIS SECTION MAY RESULT IN THE PREAUTHORIZATION BEING DENIED.
18	SECTION 9. THE ACT IS AMENDED BY ADDING SECTIONS TO READ:
19	SECTION 2161.1. INITIAL REVIEW OF PREAUTHORIZATION REQUESTS
20	AND ADVERSE DETERMINATIONS(A) A UTILIZATION REVIEW ENTITY
21	SHALL ENSURE THAT:
22	(1) A DENIAL BASED ON THE MEDICAL NECESSITY OF A
23	PREAUTHORIZATION REQUEST IS MADE BY A QUALIFIED LICENSED HEALTH
24	CARE PROVIDER WHO HAS KNOWLEDGE OF THE ITEMS, SERVICES,
25	PRODUCTS, TESTS OR PROCEDURES SUBMITTED FOR PREAUTHORIZATION.
26	(2) IF AN ADVERSE DETERMINATION IS MADE BY A PHYSICIAN AND
27	BASED ON MEDICAL NECESSITY, THEN THE PHYSICIAN MUST POSSESS A
28	CURRENT AND VALID NONRESTRICTED LICENSE TO PRACTICE MEDICINE IN
29	THIS COMMONWEALTH AND BE BOARD CERTIFIED. IF THE
30	PREAUTHORIZATION REVIEW REQUIRES A PEER-TO-PEER REVIEW IN THE

- 50 -

1	SPECIALTY OR SUBSPECIALTY WHERE A REVIEW IS REQUESTED BY THE
2	SUBMITTING PROVIDER, THEN THE PHYSICIAN CONDUCTING THE REVIEW ON
3	BEHALF OF THE UTILIZATION REVIEW ENTITY SHALL BE OF A SIMILAR
4	SPECIALTY TO THE HEALTH CARE SERVICE FOR WHICH PREAUTHORIZATION
5	<u>IS REQUESTED.</u>
6	(B) NOTIFICATION OF A PREAUTHORIZATION SHALL BE ACCOMPANIED
7	BY A UNIQUE PREAUTHORIZATION NUMBER AND INDICATE:
8	(1) THE SPECIFIC HEALTH CARE SERVICES PREAUTHORIZED.
9	(2) THE NEXT DATE FOR REVIEW.
10	(3) THE DATE OF ADMISSION OR INITIATION OF SERVICES, IF
11	APPLICABLE.
12	(C) IN THE EVENT A HEALTH CARE PROVIDER OBTAINS
13	PREAUTHORIZATION FOR ONE (1) SERVICE BUT THE SERVICE PROVIDED IS
14	NOT AN EXACT MATCH TO THE SERVICE THAT WAS PREAUTHORIZED A
15	UTILIZATION REVIEW ENTITY OR MANAGED CARE PLAN SHALL GRANT
16	AUTHORIZATION FOR THE HEALTH CARE SERVICE PROVIDED AND REMIT
17	PAYMENT AT A RATE OF REIMBURSEMENT THAT IS ASSOCIATED WITH
18	EITHER THE PREAUTHORIZED HEALTH CARE SERVICE OR THE SERVICE
19	APPROPRIATELY SUBSTITUTED BASED ON COMMON PROCEDURAL TERMINOLOGY
20	AND CLINICAL CRITERIA.
21	(D) (1) IF A UTILIZATION REVIEW ENTITY CHALLENGES THE
22	MEDICAL NECESSITY OF A HEALTH CARE SERVICE, THE UTILIZATION
23	REVIEW ENTITY SHALL NOTIFY THE ENROLLEE'S HEALTH CARE PROVIDER
24	THAT MEDICAL NECESSITY IS BEING CHALLENGED AND PROVIDE THE BASIS
25	OF THE CHALLENGE IN SUFFICIENT DETAIL TO ALLOW THE PROVIDER
26	REQUESTING AUTHORIZATION OF THE HEALTH CARE SERVICE TO
27	MEANINGFULLY ADDRESS THE CHALLENGE RAISED BY THE UTILIZATION
28	REVIEW ENTITY PRIOR TO ISSUING AN ADVERSE DETERMINATION.
29	(2) THE ENROLLEE'S HEALTH CARE PROVIDER OR DESIGNEE AND THE
30	ENROLLEE OR ENROLLEE'S DESIGNEE SHALL HAVE THE RIGHT TO DISCUSS

THE MEDICAL NECESSITY OF THE HEALTH CARE SERVICE WITH THE 1 2 UTILIZATION REVIEW PHYSICIAN. 3 (3) A UTILIZATION REVIEW ENTITY OUESTIONING MEDICAL 4 NECESSITY OF A HEALTH CARE SERVICE WHICH MAY RESULT IN AN ADVERSE DETERMINATION SHALL ENSURE A REVIEWING PHYSICIAN MAKING 5 6 THE DECISION IS AVAILABLE TELEPHONICALLY AT A SPECIFICALLY APPOINTED MUTUALLY AGREEABLE TIME SCHEDULED IN ADVANCE BETWEEN 7 8 THE PROVIDER REQUESTING THE HEALTH CARE SERVICE AND REVIEWING 9 PHYSICIAN BETWEEN THE HOURS OF SEVEN (7) O'CLOCK ANTEMERIDIAN 10 AND SEVEN (7) O'CLOCK POSTMERIDIAN. IF THE UTILIZATION REVIEW ENTITY FAILS TO MAKE THE REVIEWING PHYSICIAN AVAILABLE AS 11 REQUIRED BY THIS PARAGRAPH, THE HEALTH CARE SERVICE SUBJECT TO 12 13 THE PREAUTHORIZATION REQUEST SHALL BE DEEMED AUTHORIZED. 14 (E) WHEN MAKING A DETERMINATION BASED ON MEDICAL NECESSITY, A UTILIZATION REVIEW ENTITY SHALL BASE THE DETERMINATION ON AN 15 ENROLLEE'S PRESENTING SYMPTOMS, DIAGNOSIS AND INFORMATION 16 17 AVAILABLE THROUGH THE COURSE OF TREATMENT OR AT THE TIME OF 18 ADMISSION. SUCH INFORMATION MAY ALSO INCLUDE ANY MEDICAL INFORMATION COLLECTED AT THE TIME THE ENROLLEE PRESENTED TO THE 19 20 EMERGENCY DEPARTMENT IF THE INFORMATION IS RELEVANT TO THE 21 DETERMINATION. 22 (F) IN THE EVENT A UTILIZATION REVIEW ENTITY DETERMINES AN 23 ALTERNATIVE LEVEL OF CARE IS APPROPRIATE, THE UTILIZATION REVIEW 24 ENTITY SHALL PROVIDE NOTICE OF THE ALTERNATIVE LEVEL OF CARE TO 25 THE PROVIDER REQUESTING PREAUTHORIZATION FOR A HEALTH CARE 26 SERVICE AND CITE THE SPECIFIC CRITERIA USED AS THE BASIS FOR THE 27 ALTERNATIVE LEVEL OF CARE DETERMINATION TO THE HEALTH CARE 28 PROVIDER PRIOR TO DENYING PREAUTHORIZATION. AN ALTERNATIVE LEVEL 29 OF CARE DECISION SHALL BE SUBJECT TO A PEER-TO-PEER REVIEW AS 30 UNDER THIS SECTION.

20210SB0225PN0948

- 52 -

1	(G) A UTILIZATION REVIEW ENTITY MAY NOT ISSUE AN ADVERSE
2	DETERMINATION FOR A PROCEDURE DUE TO LACK OF PREAUTHORIZATION IF
3	THE PROCEDURE IS MEDICALLY NECESSARY OR CLINICALLY APPROPRIATE
4	FOR THE PATIENT'S MEDICAL CONDITION AND RENDERED AT THE SAME
5	TIME AS A RELATED PROCEDURE FOR WHICH PREAUTHORIZATION WAS
6	REQUIRED AND RECEIVED.
7	(H) A UTILIZATION REVIEW ENTITY SHALL MAKE A
8	PREAUTHORIZATION ADVERSE DETERMINATION DECISION AND NOTIFY THE
9	ENROLLEE AND THE ENROLLEE'S HEALTH CARE PROVIDER AS FOLLOWS:
10	(1) FOR NONURGENT HEALTH CARE SERVICES, WITHIN FIVE (5) DAYS
11	OF OBTAINING ALL THE NECESSARY INFORMATION TO MAKE THE
12	PREAUTHORIZATION OR ADVERSE DETERMINATION, SO LONG AS THE ENTIRE
13	REVIEW PROCESS IS COMPLETED EITHER SEVEN (7) DAYS FOLLOWING THE
14	INITIAL REQUEST IF NO ADDITIONAL INFORMATION IS REQUESTED BY THE
15	UTILIZATION REVIEW ENTITY OR NINE (9) DAYS FOLLOWING THE INITIAL
16	SUBMISSION IF ADDITIONAL INFORMATION IS REQUESTED.
16 17	SUBMISSION IF ADDITIONAL INFORMATION IS REQUESTED. (2) FOR URGENT HEALTH CARE SERVICES, WITHIN FORTY-EIGHT (48)
17	(2) FOR URGENT HEALTH CARE SERVICES, WITHIN FORTY-EIGHT (48)
17 18	(2) FOR URGENT HEALTH CARE SERVICES, WITHIN FORTY-EIGHT (48) HOURS FROM SUBMISSION OF THE REQUEST FOR PRIOR AUTHORIZATION. NO
17 18 19	(2) FOR URGENT HEALTH CARE SERVICES, WITHIN FORTY-EIGHT (48) HOURS FROM SUBMISSION OF THE REQUEST FOR PRIOR AUTHORIZATION. NO UTILIZATION REVIEW ENTITY MAY REQUIRE PREAUTHORIZATION FOR AN
17 18 19 20	(2) FOR URGENT HEALTH CARE SERVICES, WITHIN FORTY-EIGHT (48) HOURS FROM SUBMISSION OF THE REQUEST FOR PRIOR AUTHORIZATION. NO UTILIZATION REVIEW ENTITY MAY REQUIRE PREAUTHORIZATION FOR AN EMERGENCY SERVICE, INCLUDING POST EVALUATION AND
17 18 19 20 21	(2) FOR URGENT HEALTH CARE SERVICES, WITHIN FORTY-EIGHT (48) HOURS FROM SUBMISSION OF THE REQUEST FOR PRIOR AUTHORIZATION. NO UTILIZATION REVIEW ENTITY MAY REQUIRE PREAUTHORIZATION FOR AN EMERGENCY SERVICE, INCLUDING POST EVALUATION AND POSTSTABILIZATION SERVICES.
17 18 19 20 21 22	(2) FOR URGENT HEALTH CARE SERVICES, WITHIN FORTY-EIGHT (48) HOURS FROM SUBMISSION OF THE REQUEST FOR PRIOR AUTHORIZATION. NO UTILIZATION REVIEW ENTITY MAY REQUIRE PREAUTHORIZATION FOR AN EMERGENCY SERVICE, INCLUDING POST EVALUATION AND POSTSTABILIZATION SERVICES. SECTION 2161.2. PREAUTHORIZATION DENIAL GRIEVANCES(A) AN
17 18 19 20 21 22 23	(2) FOR URGENT HEALTH CARE SERVICES, WITHIN FORTY-EIGHT (48) HOURS FROM SUBMISSION OF THE REQUEST FOR PRIOR AUTHORIZATION. NO UTILIZATION REVIEW ENTITY MAY REQUIRE PREAUTHORIZATION FOR AN EMERGENCY SERVICE, INCLUDING POST EVALUATION AND POSTSTABILIZATION SERVICES. SECTION 2161.2. PREAUTHORIZATION DENIAL GRIEVANCES(A) AN ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER MAY SUBMIT A
17 18 19 20 21 22 23 24	(2) FOR URGENT HEALTH CARE SERVICES, WITHIN FORTY-EIGHT (48) HOURS FROM SUBMISSION OF THE REQUEST FOR PRIOR AUTHORIZATION. NO UTILIZATION REVIEW ENTITY MAY REQUIRE PREAUTHORIZATION FOR AN EMERGENCY SERVICE, INCLUDING POST EVALUATION AND POSTSTABILIZATION SERVICES. SECTION 2161.2. PREAUTHORIZATION DENIAL GRIEVANCES(A) AN ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER MAY SUBMIT A GRIEVANCE AND REQUEST AN EXPEDITED REVIEW OF AN ADVERSE
17 18 19 20 21 22 23 24 25	(2) FOR URGENT HEALTH CARE SERVICES, WITHIN FORTY-EIGHT (48) HOURS FROM SUBMISSION OF THE REQUEST FOR PRIOR AUTHORIZATION. NO UTILIZATION REVIEW ENTITY MAY REQUIRE PREAUTHORIZATION FOR AN EMERGENCY SERVICE, INCLUDING POST EVALUATION AND POSTSTABILIZATION SERVICES. SECTION 2161.2. PREAUTHORIZATION DENIAL GRIEVANCES(A) AN ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER MAY SUBMIT A GRIEVANCE AND REQUEST AN EXPEDITED REVIEW OF AN ADVERSE DETERMINATION VIA TELEPHONE, FACSIMILE, ELECTRONIC MAIL OR OTHER
17 18 19 20 21 22 23 24 25 26	(2) FOR URGENT HEALTH CARE SERVICES, WITHIN FORTY-EIGHT (48) HOURS FROM SUBMISSION OF THE REQUEST FOR PRIOR AUTHORIZATION. NO UTILIZATION REVIEW ENTITY MAY REQUIRE PREAUTHORIZATION FOR AN EMERGENCY SERVICE, INCLUDING POST EVALUATION AND POSTSTABILIZATION SERVICES. SECTION 2161.2. PREAUTHORIZATION DENIAL GRIEVANCES (A) AN ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER MAY SUBMIT A GRIEVANCE AND REQUEST AN EXPEDITED REVIEW OF AN ADVERSE DETERMINATION VIA TELEPHONE, FACSIMILE, ELECTRONIC MAIL OR OTHER METHOD. WITHIN ONE (1) DAY OF RECEIVING AN EXPEDITED REQUEST AND
17 18 19 20 21 22 23 24 25 26 27	(2) FOR URGENT HEALTH CARE SERVICES, WITHIN FORTY-EIGHT (48) HOURS FROM SUBMISSION OF THE REQUEST FOR PRIOR AUTHORIZATION. NO UTILIZATION REVIEW ENTITY MAY REQUIRE PREAUTHORIZATION FOR AN EMERGENCY SERVICE, INCLUDING POST EVALUATION AND POSTSTABILIZATION SERVICES. SECTION 2161.2. PREAUTHORIZATION DENIAL GRIEVANCES (A) AN ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER MAY SUBMIT A GRIEVANCE AND REQUEST AN EXPEDITED REVIEW OF AN ADVERSE DETERMINATION VIA TELEPHONE, FACSIMILE, ELECTRONIC MAIL OR OTHER METHOD. WITHIN ONE (1) DAY OF RECEIVING AN EXPEDITED REQUEST AND ALL INFORMATION NECESSARY TO MAKE A DETERMINATION, THE

- 53 -

1	(B) A GRIEVANCE SHALL BE REVIEWED ONLY BY A PHYSICIAN WHO
2	SATISFIES ANY OF THE FOLLOWING CONDITIONS:
3	(1) IS BOARD CERTIFIED IN THE SAME SPECIALTY AS A HEALTH
4	CARE PRACTITIONER WHO TYPICALLY MANAGES THE MEDICAL CONDITION OR
5	DISEASE.
6	(2) IS CURRENTLY IN ACTIVE PRACTICE, PROVIDED THAT IN EVENTS
7	WHERE CIRCUMSTANCES JUSTIFY IT OR WHERE THE PROVIDER SEEKING
8	PREAUTHORIZATION SPECIFICALLY REQUESTS A HEALTH CARE PROVIDER
9	ACTIVELY ENGAGED IN THE SPECIALTY WHO TYPICALLY MANAGES THE
10	MEDICAL CONDITION OR DISEASE, THE PHYSICIAN SHALL BE MADE
11	AVAILABLE FOR THE REVIEW.
12	(3) IS KNOWLEDGEABLE OF, AND HAS EXPERIENCE IN, PROVIDING
13	THE HEALTH CARE SERVICES UNDER GRIEVANCE.
14	(4) IS UNDER CONTRACT WITH A UTILIZATION REVIEW ENTITY TO
15	PERFORM REVIEWS OF GRIEVANCES AND PAYMENT OF FEES DUE UNDER THE
16	CONTRACT, BUT THE PERFORMANCE AND PAYMENT IS NOT SUBJECT TO OR
17	CONTINGENT UPON THE OUTCOME OF THE APPEAL. THE FOLLOWING SHALL
18	<u>APPLY:</u>
19	(I) THE PHYSICIAN MAY ALSO BE SUBJECT TO A PROVIDER
20	AGREEMENT WITH THE MANAGED CARE PLAN AS A NETWORK PROVIDER, BUT
21	SHALL NOT RECEIVE ANY OTHER FEE OR COMPENSATION FROM THE MANAGED
22	CARE PLAN.
23	(II) THE PHYSICIAN'S RECEIPT OF COMPENSATION FROM EITHER THE
24	MANAGED CARE PLAN OR THE UTILIZATION REVIEW ENTITY SHALL NOT BE
25	CONSIDERED BY THE PHYSICIAN IN DETERMINING THE CONCLUSION
26	REACHED BY THE PHYSICIAN.
27	(III) THE PHYSICIAN SHALL AT ALL TIMES RENDER INDEPENDENT
28	AND ACCURATE MEDICAL JUDGMENT IN REACHING AN OPINION OR
29	CONCLUSION.
30	(IV) FAILURE TO COMPLY WITH THIS PROVISION SHALL RENDER THE

- 54 -

1 PHYSICIAN SUBJECT TO LICENSURE DISCIPLINARY ACTION BY THE

2 APPROPRIATE LICENSING BOARD.

3 (5) NOT INVOLVED IN MAKING THE ADVERSE DETERMINATION.

4 (6) FAMILIAR WITH ALL KNOWN CLINICAL ASPECTS OF THE HEALTH

5 CARE SERVICES UNDER REVIEW, INCLUDING ALL PERTINENT MEDICAL

6 RECORDS PROVIDED TO THE UTILIZATION REVIEW ENTITY BY THE

7 ENROLLEE'S HEALTH CARE PROVIDER AND ANY RELEVANT RECORD PROVIDED

8 TO THE UTILIZATION REVIEW ENTITY BY A HEALTH CARE FACILITY.

9 (C) THE UTILIZATION REVIEW ENTITY SHALL ENSURE THAT

10 <u>GRIEVANCE REVIEW PROCEDURES SATISFY THE FOLLOWING REQUIREMENTS:</u>

11 (1) THE ENROLLEE AND THE ENROLLEE'S HEALTH CARE PROVIDER MAY

12 CHALLENGE THE ADVERSE DETERMINATION AND HAVE THE RIGHT TO APPEAR

13 IN PERSON BEFORE THE UTILIZATION REVIEW ENTITY, INCLUDING THE

14 <u>REVIEWING PHYSICIAN, WHO REVIEWS THE ADVERSE DETERMINATION.</u>

15 (2) THE UTILIZATION REVIEW ENTITY SHALL PROVIDE THE ENROLLEE

16 AND THE ENROLLEE'S HEALTH CARE PROVIDER WRITTEN NOTICE OF THE

17 TIME AND PLACE CONCERNING WHERE THE REVIEW MEETING WILL TAKE

18 PLACE. NOTICE SHALL BE GIVEN TO THE ENROLLEE'S HEALTH CARE

19 PROVIDER AT LEAST FOURTEEN (14) DAYS IN ADVANCE OF THE REVIEW

20 <u>MEETING.</u>

21 (3) IF THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER

22 APPEAR IN PERSON, THE UTILIZATION REVIEW ENTITY SHALL OFFER THE

23 ENROLLEE OR ENROLLEE'S HEALTH CARE PROVIDER THE OPPORTUNITY TO

24 <u>COMMUNICATE WITH THE REVIEWING PHYSICIAN, AT THE UTILIZATION</u>

25 REVIEW ENTITY'S EXPENSE, BY CONFERENCE CALL, VIDEO CONFERENCING

26 OR OTHER AVAILABLE TECHNOLOGY.

27 (4) THE PHYSICIAN PERFORMING THE REVIEW OF THE GRIEVANCE

28 SHALL CONSIDER ALL INFORMATION, DOCUMENTATION OR OTHER MATERIAL

29 <u>SUBMITTED IN CONNECTION WITH THE GRIEVANCE WITHOUT REGARD TO</u>

30 WHETHER THE INFORMATION WAS CONSIDERED IN MAKING THE ADVERSE

- 55 -

1 <u>DETERMINATION.</u>

2	(D) THE FOLLOWING DEADLINES SHALL APPLY TO THE UTILIZATION
3	REVIEW ENTITIES:
4	(1) A UTILIZATION REVIEW ENTITY SHALL DECIDE A GRIEVANCE
5	SUBMITTED FOR EXPEDITED REVIEW AND NOTIFY THE ENROLLEE AND THE
6	ENROLLEE'S HEALTH CARE PROVIDER OF THE DETERMINATION WITHIN TWO
7	(2) DAYS AFTER RECEIVING A NOTICE OF THE EXPEDITED REVIEW
8	REQUEST BY THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER
9	AND ALL INFORMATION NECESSARY TO RENDER A DECISION.
10	(2) A UTILIZATION REVIEW ENTITY SHALL ISSUE A WRITTEN
11	DETERMINATION CONCERNING A NONEXPEDITED GRIEVANCE NOT LATER THAN
12	THIRTY (30) DAYS AFTER RECEIVING A NOTICE OF THE GRIEVANCE FROM
13	AN ENROLLEE OR ENROLLEE'S HEALTH CARE PROVIDER.
14	(E) WRITTEN NOTICE OF FINAL AN ADVERSE DETERMINATION SHALL
15	BE PROVIDED TO THE ENROLLEE AND THE ENROLLEE'S HEALTH CARE
16	PROVIDER.
ΤÜ	
17	(F) IF THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER
17	(F) IF THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER
17 18	(F) IF THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE ON BEHALF OF EITHER THE ENROLLEE OR THE ENROLLEE'S
17 18 19	(F) IF THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE ON BEHALF OF EITHER THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER HAS SATISFIED ALL NECESSARY REQUIREMENTS
17 18 19 20	(F) IF THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE ON BEHALF OF EITHER THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER HAS SATISFIED ALL NECESSARY REQUIREMENTS FOR THE GRIEVANCE REVIEW DETERMINATION OF AN ADVERSE
17 18 19 20 21	(F) IF THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE ON BEHALF OF EITHER THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER HAS SATISFIED ALL NECESSARY REQUIREMENTS FOR THE GRIEVANCE REVIEW DETERMINATION OF AN ADVERSE DETERMINATION THROUGH THE PREAUTHORIZATION PROCESS AND THE
17 18 19 20 21 22	(F) IF THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE ON BEHALF OF EITHER THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER HAS SATISFIED ALL NECESSARY REQUIREMENTS FOR THE GRIEVANCE REVIEW DETERMINATION OF AN ADVERSE DETERMINATION THROUGH THE PREAUTHORIZATION PROCESS AND THE DETERMINATION HAS RESULTED IN A CONTINUED ADVERSE DETERMINATION
17 18 19 20 21 22 23	(F) IF THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE ON BEHALF OF EITHER THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER HAS SATISFIED ALL NECESSARY REQUIREMENTS FOR THE GRIEVANCE REVIEW DETERMINATION OF AN ADVERSE DETERMINATION THROUGH THE PREAUTHORIZATION PROCESS AND THE DETERMINATION HAS RESULTED IN A CONTINUED ADVERSE DETERMINATION EITHER BASED ON LACK OF MEDICAL NECESSITY OR AN ADMINISTRATIVE
17 18 19 20 21 22 23 24	(F) IF THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE ON BEHALF OF EITHER THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER HAS SATISFIED ALL NECESSARY REQUIREMENTS FOR THE GRIEVANCE REVIEW DETERMINATION OF AN ADVERSE DETERMINATION THROUGH THE PREAUTHORIZATION PROCESS AND THE DETERMINATION HAS RESULTED IN A CONTINUED ADVERSE DETERMINATION EITHER BASED ON LACK OF MEDICAL NECESSITY OR AN ADMINISTRATIVE DEFECT, THE ENROLLEE, THE ENROLLEE'S HEALTH CARE PROVIDER OR A
17 18 19 20 21 22 23 24 25	(F) IF THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE ON BEHALF OF EITHER THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER HAS SATISFIED ALL NECESSARY REQUIREMENTS FOR THE GRIEVANCE REVIEW DETERMINATION OF AN ADVERSE DETERMINATION THROUGH THE PREAUTHORIZATION PROCESS AND THE DETERMINATION HAS RESULTED IN A CONTINUED ADVERSE DETERMINATION EITHER BASED ON LACK OF MEDICAL NECESSITY OR AN ADMINISTRATIVE DEFECT, THE ENROLLEE, THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE ON BEHALF OF EITHER THE ENROLLEE OR THE ENROLLEE'S
17 18 19 20 21 22 23 24 25 26	(F) IF THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE ON BEHALF OF EITHER THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER HAS SATISFIED ALL NECESSARY REQUIREMENTS FOR THE GRIEVANCE REVIEW DETERMINATION OF AN ADVERSE DETERMINATION THROUGH THE PREAUTHORIZATION PROCESS AND THE DETERMINATION HAS RESULTED IN A CONTINUED ADVERSE DETERMINATION EITHER BASED ON LACK OF MEDICAL NECESSITY OR AN ADMINISTRATIVE DEFECT, THE ENROLLEE, THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE ON BEHALF OF EITHER THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE MAY FILE A CONSUMER COMPLAINT
17 18 19 20 21 22 23 24 25 26 27	(F) IF THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE ON BEHALF OF EITHER THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER HAS SATISFIED ALL NECESSARY REQUIREMENTS FOR THE GRIEVANCE REVIEW DETERMINATION OF AN ADVERSE DETERMINATION THROUGH THE PREAUTHORIZATION PROCESS AND THE DETERMINATION HAS RESULTED IN A CONTINUED ADVERSE DETERMINATION EITHER BASED ON LACK OF MEDICAL NECESSITY OR AN ADMINISTRATIVE DEFECT, THE ENROLLEE, THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE ON BEHALF OF EITHER THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE MAY FILE A CONSUMER COMPLAINT WITH THE DEPARTMENT OF HEALTH IF FOR CONTINUED LACK OF MEDICAL
17 18 19 20 21 22 23 24 25 26 27 28	(F) IF THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE ON BEHALF OF EITHER THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER HAS SATISFIED ALL NECESSARY REQUIREMENTS FOR THE GRIEVANCE REVIEW DETERMINATION OF AN ADVERSE DETERMINATION THROUGH THE PREAUTHORIZATION PROCESS AND THE DETERMINATION HAS RESULTED IN A CONTINUED ADVERSE DETERMINATION EITHER BASED ON LACK OF MEDICAL NECESSITY OR AN ADMINISTRATIVE DEFECT, THE ENROLLEE, THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE ON BEHALF OF EITHER THE ENROLLEE OR THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE MAY FILE A CONSUMER COMPLAINT WITH THE DEPARTMENT OF HEALTH IF FOR CONTINUED LACK OF MEDICAL NECESSITY AND THE INSURANCE DEPARTMENT IF FOR ADMINISTRATIVE

- 56 -

1	BY THE RELEVANT DEPARTMENT WITH APPROPRIATE SANCTIONS, IF
2	APPLICABLE, UNDER THE AUTHORITY GIVEN TO THAT DEPARTMENT.
3	(G) TO THE EXTENT THAT AN ENROLLEE, AN ENROLLEE'S HEALTH
4	CARE PROVIDER OR A DESIGNEE ON BEHALF OF EITHER THE ENROLLEE OR
5	THE ENROLLEE'S HEALTH CARE PROVIDER OR A DESIGNEE FILES A
6	CONSUMER COMPLAINT WITH EITHER DEPARTMENT OR THE OFFICE OF
7	ATTORNEY GENERAL UNDER THE AUTHORITY TO RECEIVE THE COMPLAINTS,
8	A COPY OF THE COMPLAINT FILED WITH EITHER DEPARTMENT OR THE
9	OFFICE OF ATTORNEY GENERAL SHALL BE FORWARDED TO THE INSURANCE
10	DEPARTMENT AND THE COPY SHALL SERVE AS A NEW CONSUMER COMPLAINT
11	TO BE ADJUDICATED UNDER THE TERMS OF THIS SECTION AND ALL OTHER
12	APPLICABLE LAW.
13	SECTION 2195. ACCESS REQUIREMENTS IN SERVICE AREASIF AN
14	ENROLLEE'S SAFE DISCHARGE IS DELAYED FOR ANY REASON, INCLUDING
15	LACK OF AVAILABLE POSTHOSPITALIZATION SERVICES, INCLUDING
16	SKILLED NURSING FACILITIES, HOME HEALTH SERVICES AND POSTACUTE
17	REHABILITATION, THE MANAGED CARE PLAN SHALL REIMBURSE THE
18	HOSPITAL FOR EACH SUBSEQUENT DATE OF SERVICE AT THE GREATER OF
19	THE CONTRACTED RATE WITH THE MANAGED CARE PLAN FOR THE CURRENT
20	LEVEL OF CARE AND SERVICE OR THE FULL DIAGNOSTIC RELATED GROUP
21	PAYMENT DIVIDED BY THE MEAN LENGTH OF STAY FOR THE PARTICULAR
22	DIAGNOSTIC RELATED GROUP.
23	SECTION 11. NOTHING IN THIS ACT SHALL BE CONSTRUED TO
24	PRECLUDE AN INSURER FROM DEVELOPING A PROGRAM EXEMPTING A HEALTH
25	CARE PROVIDER FROM PREAUTHORIZATION PROTOCOLS.
0.0	

26 SECTION 12. THIS ACT SHALL TAKE EFFECT IN 60 DAYS.

- 57 -